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Abstract 
 
Nonsense mediated mRNA decay (NMD) is an important mRNA quality control 
pathway conserved in eukaryotes. NMD targets aberrant mRNAs carrying premature 
stop codons (PTCs) for rapid degradation, preventing the accumulation of C-terminally 
truncated protein products that would otherwise be toxic to cells. NMD involves the 
concerted action of several trans-acting factors and it is a highly regulated process. A 
decisive event to trigger NMD in metazoans is the phosphorylation of the RNA 
helicase UPF1 by the SMG1 kinase. SMG8 and SMG9 form a heterodimer that 
interacts with SMG1 and inhibits its kinase activity. In recent years, electron 
microscopy studies of the human SMG1-SMG8-SMG9 complex provided low-
resolution structural information that revealed the overall architecture of this complex. 
Still not much is known about the structure and function of SMG8 and SMG9 and how 
they interact with each other as well as with SMG1. In this thesis, I used biochemical 
approaches to identify the core of a SMG8-SMG9 complex amenable to crystallization 
and determined its three-dimensional structure at the resolution of 2.5 Å. I found that 
the C. elegans SMG8-SMG9 core complex resembles a G-domain heterodimer with a 
potentially active subunit (SMG9) and an inactive subunit (SMG8). Following this 
result, I characterized the nucleotide-binding properties of SMG-SMG9 using 
biophysical and structural methods. Fitting the atomic model in a previously published 
low-resolution EM map of a SMG1-SMG8-SMG9 complex raises interesting 
possibility that the nucleotide-binding state of SMG8-SMG9 might impact on the 
function of the kinase.  
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1 Introduction 
 
Genetic information in protein encoding genes is transferred to messenger RNA 
(mRNA) through the process of transcription and ultimately decoded to protein via the 
process of translation. The fidelity of gene transcription and translation is vital for 
cellular activities. Errors could occur and accumulate during transcription or splicing 
that lead to mutations on mRNA. Proteins translated from aberrant mRNA templates 
be misfolded or be truncated in the case of nonsense mutations. Eukaryotic organisms 
have evolved multiple quality control systems to detect aberrant mRNAs and subject 
them to rapid degradation. Three predominant translation-coupled mRNA quality 
control pathways have been discovered in eukaryotes termed Nonsense mediated 
mRNA decay (NMD), No-go decay (NGD) and Nonstop decay (NSD). NMD targets 
mRNAs that harbor a premature translation stop codon (PTC) for degradation and thus 
prevent production of C-terminally truncated proteins that might be toxic to cells 1. 
NGD recognizes and degrades mRNAs that contain structured features that block 
translating ribosomes 2,3,4. NSD targets mRNAs that lack a stop codon causing 
ribosomes to run to the end of mRNAs and stall 5,6. This thesis work is focused on 
NMD and the main progress in NMD research that has been reported over the last three 
decades will be discussed in this chapter. 
1.1 Nonsense mediated mRNA decay (NMD) 
 
It was first observed over 30 years ago in yeast and human cells that half-lives of 
affected mRNAs can be reduced by nonsense mutation that terminates translation 
prematurely7,8. The term “Nonsense mediated mRNA decay” was first used in 1993 by 
Peltz et al. to describe the phenomenon that nonsense mutations can accelerate the 
decay rate of mRNAs9. NMD has been found in all eukaryotes examined and the core 
NMD machinery is conserved from yeast to humans10. Since NMD was discovered, it 
has been defined based on its function as a eukaryotic surveillance mechanism 
targeting mRNAs that contain a premature translation termination codon (PTC). 
However, in the last 10 years evidences from genome-wide analysis in different 
eukaryotic organisms suggest that NMD not only can target aberrant mRNAs 
harboring PTCs but also affects the stability of normal mRNAs that encode complete 
protein products, thereby regulating expression levels of a significant amount of 
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endogenous mRNAs11 12-14. Therefore our knowledge to the function of NMD has 
expanded from a classical eukaryotic mRNA quality control pathway to post-
transcriptional regulation of gene expression. However, despite extensive researches 
have been conducted on NMD and a plethora of structural and biochemical data are 
available, the molecular mechanism of NMD is still elusive due to its complexity and 
difficulty to recapitulate the whole process in vitro.  
 
 
Figure 1.1: The dual role of NMD15 (figure adapted from Ref. 15). NMD is not only 
a surveillance pathway that degrades aberrant transcripts but also involved in the post-
transcriptional regulation of gene expression by influencing the stability of many 
normal transcripts. 
1.1.1   NMD-inducing features 
 
It is widely accepted that NMD targets aberrant PTC-containing and also apparently 
normal mRNAs. It has been estimated that depending on organisms or cell types, 
around 5%-20% of transcripts in a typical transcriptome are substrates of NMD16. 
NMD can be elicited only when a stop codon on mRNAs is in a context that can 
activate the NMD machinery. However, the NMD-inducing features of transcripts that 
have been discovered are rather diverse. The features of NMD substrates that have 
been reported can be described in the following two classes. The first class, which is 
also the classical one, includes typical substrates that contain a destabilizing stop codon 
inside the coding region. The premature stop codon can be generated by nonsense or 
frame shift mutations in endogenous genes, or by errors from transcription or 
alternative splicing events17. The second class contains physiologically relevant and 
apparently normal mRNAs such as mRNAs with upstream open reading frames 
(uORFs)18,19 and mRNAs with long 3′ untranslated regions (3′-UTRs)20,21. Despite the 
fact that with current knowledge there is no unified NMD-inducing feature that can 
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define a NMD substrate and not all PTCs or uORFs can trigger NMD, one requirement 
for NMD to be initiated is that the NMD machinery needs to be recruited to the 
ribosome, which stalls on a stop codon and is not able to dissociate efficiently as in 
normal translation termination.  
1.1.2   NMD machinery 
 
NMD is a translation-dependent process conserved in eukaryotic organisms from yeast 
to humans. In order to activate efficient degradation of NMD substrates, multiple trans-
acting factors have been employed by eukaryotic cells to assemble the NMD 
machinery to be recruited to the aberrantly terminated ribosome on a stop codon. 
Genetic screens in yeast identified the first three NMD factors called up-frameshift 
(UPF) proteins UPF1, UPF2 and UPF322,23 and genetic screens in C. elegans identified 
7 NMD effectors that are named from SMG1-SMG7 (suppressor with morphological 
effect on genitalia)24,25. SMG2, SMG3 and SMG4 in C. elegans are the homologues for 
yeast UPF1, UPF2 and UPF3 respectively26. A few novel NMD factors including 
SMG8 and SMG9 have been identified in recent years with genetic screen or Co-IP 
with known NMD factors or homology search with bioinformatic methods27,28, the 
mechanistic roles of which still need to be characterized. The NMD pathway in 
different organisms requires different factors that constitute its NMD machinery. Some 
factors such as the UPF proteins are conserved in all eukaryotes that have been studied 
that constitute the core NMD machinery while other factors such as homologues of 
SMG1, SMG5-7 proteins present only in higher eukaryotes and the exon junction 
complex (EJC) is required for NMD only in mammalian cells1.  
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Figure 1.2: NMD factors (figure adapted from Ref. 28). NMD factors that have been 
identified in Saccharomyces cerevisiae, Caenorhabditis elegans and Homo Sapiens 
with different methods28.  
1.1.2.1 Core UPF proteins 
 
UPF1 is a monomeric SF1 (superfamily 1) RNA helicase that plays the central role in 
NMD in all eukaryotes. UPF1 has a modular domain organization with a central 
helicase domain that is flanked by a conserved N-terminal cysteine-histidine-rich (CH) 
domain and a C-terminal serine-glutamine-rich (SQ) domain, which in metazoans gets 
phosphorylated by SMG1 at multiple SQ-motifs29. The UPF1 helicase and ATPase 
activities are essential for NMD in both yeast and humans30,31 and are highly regulated 
by intra-molecular and intermolecular interactions32. The central helicase domain is 
comprised of two flexible RecA domains with the ATP binding site located in the cleft 
between these two domains29. The UPF1 binding affinity for RNA is reduced in the 
ATP-bound form33,34. The CH domain and SQ domain together suppress UPF1 
helicase activity in vitro. Binding of UPF2 to the CH domain of UPF1 induces a large 
conformational change in UPF1 that promotes its ATPase and helicase activity, which 
is also a prerequisite for UPF1 phosphorylation29,33.  
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UPF2 is the second core NMD factor that functions as a ring-like scaffold bridging 
UPF1 and UPF333,35. UPF2 is comprised of three MIF4G (middle portion of eIF4G) 
domains, first two of which provide structural support36 and the third domain interacts 
with UPF3B37. The C-terminal part of UPF2 called UBD interacts with UPF138. 
UPF3 is the third core NMD factor. In humans, due to alternative splicing two 
isoforms of UPF3 co-exist, UPF3A and UPF3B39,40. However, UPF3B is the dominant 
isoform that functions in NMD in human cells. Only when UPF3B is depleted, UPF3A 
is stabilized and substitute UPF3B in NMD41,42. UPF3 shuttles between nucleus and 
cytoplasm but in steady state is found primarily in nucleus38 where it is thought to 
associate with EJCs upon pre-mRNA splicing. UPF3 contains a N-terminal RNA 
recognition motif (RRM) that is the binding surface for UPF2 instead of RNA37 and a 
short motif at the C-terminus called EJC binding motif (EBM) that interacts with 
EJC33,43. Therefore, UPF3 is the bridging molecule linking EJC and UPF2.  
 
 
Figure 1.3: Domain architectures of human UPF proteins1 (figure adapted from 
Ref. 1). CH: cysteine-histidine rich domain; SQ: serine-glutamine rich domain; 
MIF4G: middle of 4G-like domains; UBD: UPF1-binding domain; RRM: RNA 
recognition motif; EBM: exon junction binding motif. 
1.1.2.2 Additional SMG proteins 
 
SMG1 is one of essential players for triggering NMD response in metazoans44,45. 
SMG1 was first identified by genetic screen in C. elegans24,25 and its human 
homologue was found by homology28. Human SMG1 is a large protein of ~410 kDa in 
molecular weight and belongs to the phosphatidylinositol 3-kinase-related protein 
kinase (PIKK) family of serine–threonine kinases. Similar to other members in the 
PIKK family, the primary structure of SMG1 contains a conserved C terminus 
preceded by a long stretch of helical repeats. The conserved C terminus is comprised of 
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a FAT (FRAP/TOR, ATM, and TRRAP) domain, a FRB (FKBP-rapamycin-binding) 
domain and a catalytic PI3K (phosphatidylinositol 3-kinase)-like kinase domain 
followed by a short C-terminal FATC (C-terminal FAT) domain. Besides these 
common structural features, a unique insertion region is located between the kinase 
domain and the FATC46,47. The SMG1-mediated UPF1 phosphorylation has been 
believed to be the definitive signal to trigger NMD45.  
The SMG8 and SMG9 factors were originally identified by interaction studies with 
human SMG127. Homologues of SMG8 and SMG9 also exist in C. elegans. SMG8 and 
SMG9 have been reported as two regulators for SMG1 kinase27,47. The interactions 
between SMG8-SMG9 and SMG1 keep SMG1 kinase in the inactive state27,47. 
However, the mechanism for inhibition and activation of SMG1 kinase activity 
remains elusive due to the lack of high-resolution structural information. SMG8 was 
predicted to contain two conserved regions27. However, the boundary and function of 
each conserved region are unknown. SMG9 was predicted to contain a N-terminal 
unstructured region and a C-terminal NTPase domain48. Both the N-terminal region 
and the C-terminal domain of SMG9 are required for binding to SMG148. SMG9 is the 
central molecule for the assembly of so-called SMG1C (SMG1-8-9 complex). SMG9 
can bind SMG1 by itself or in the form of a preassembled SMG8-SMG9 complex. 
Binding of SMG8 to SMG1-SMG9 was reported to induce a large conformational 
change on SMG1, which is thought to cause the inhibition of the kinase activity of 
SMG147.  
Finally, the NMD factors SMG5, SMG6 and SMG7 are recruited by phosphorylated 
UPF1. These proteins share a common phosphoserine-binding domain that adopts a 
similar fold to 14-3-3 proteins49. The 14-3-3-like domains of SMG5 and SMG7 interact 
with each other back to back forming a stable heterodimer and recognize the 
phosphorylated residues in the C-terminus of UPF150. SMG5 and SMG7 can recruit 
protein phosphatase 2A (PP2A) to mediate dephosphorylation of UPF151. SMG7 was 
recently shown to be involved in deadenylation by recruiting the CCR4-NOT 
deadenylase complex52. While SMG5 and SMG7 work together in a heterodimer, 
SMG6 functions as a monomer and contains distinct functional modules. It contains 
two N-terminal protein-protein interaction motifs (EBM)53, a central TPR domain and 
a C-terminal PIN domain54. The SMG6 PIN domain adopts a similar fold to RNase H 
family endonuclease and mediates active endonucleolytic mRNA cleavage in the 
vicinity of NMD-inducing PTC55-57. In contrast, the C-terminal PIN-like domain of 
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SMG5 does not have endonuclease activity due to lacking the canonical motif of three 
aspartic acid residues56. Recent studies have shown that SMG6 is able to interact with 
UPF1 in a phosphorylation-dependent and in a phosphorylation-independent 
manner54,58. SMG6 and SMG5-SMG7 can bind UPF1 concomitantly54. SMG6 interacts 
with EJC through its N-terminal two conserved EJC binding motifs53.  
         
Figure 1.4: Domain organization of human SMG proteins54. HEAT: Huntingtin, 
elongation factor 3 (EF3), protein phosphatase 2A (PP2A), yeast kinase TOR1 domain; 
FAT: FRAP/TOR, ATM, and TRRAP; FRB: FKBP-rapamycin-binding domain; 
PIKK: phosphatidylinositol 3-kinase-related protein kinase domain; FATC: C-terminal 
FAT domain; CR: conserved region; PIN: PilT N-terminus domain; TPR: 
Tetratricopeptide repeat. 
1.1.2.3 Exon junction complex (EJC) 
 
In mammalian cells, the nuclear splicing machinery leaves a molecular mark on spliced 
mRNA59. This molecular mark is a multiprotein complex named exon junction 
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complex (EJC) deposited by spliceosomes during splicing onto mRNAs at a conserved 
position of 24nt upstream spliced junctions59.  The EJC is a dynamic complex involved 
in various post-transcriptional processes, including splicing, transport, translation and 
NMD60. The EJC is transported together with its bound mRNA to cytoplasm, 
subsequently dissociates from mRNA during the first round of translation. The EJC is 
considered a strong enhancer of NMD in mammalian cells by providing a dynamic 
binding platform for the assembly of UPF complex, which is a part of the NMD 
complex when a ribosome stalls at the premature stop codon60. Despite the important 
role that EJC plays in NMD, the requirement for EJC in NMD is diverse in different 
eukaryotic organisms. There is no EJC in yeast while in Caenorhabditis elegans61 and 
Drosophila melanogaster62 the EJC is dispensable for NMD. The stable core of the 
EJC is composed of four proteins: eIF4AIII (eukaryotic initiation factor 4AIII), Mago, 
Y14 (also known as RNA-binding motif 8A) and Barentsz (Btz, also known as 
MLN51)63,64. Structural studies have revealed the assembly of EJC core and its 
interaction with RNA65,66. The EJC core binds RNA through eIF4AIII and Btz. 
eIF4AIII is a DEAD-box RNA helicase containing two RecA-like domains that adopt a 
closed conformation upon ATP binding and binds the sugar-phosphate backbones 
independently of bases. This conformation is stabilized through the interaction between 
two eIF4AIII RecA-like domains and Mago-Y14 heterodimer that prevents the 
conformational change induced by ATP hydrolysis thereby lock the helicase on the 
RNA. The EJC complex is further stabilized by Btz, which interacts with eIF4AIII 
through its two conserved regions.  
1.1.2.4 Novel NMD factors 
 
In addition to current well known NMD factors, a few novel NMD trans-acting factors 
have been identified by a variety of strategies including RNAi screen and Interactome-
Mass spectrometry approach. However, the mechanisms underlying their functions 
remain to be investigated. With a GFP-reporter-based RNAi screen in C. elegans, two 
novel factors smgl-1 and smgl-2 were identified and they are conserved throughout 
evolution61. The human orthologues for C. elegans smgl-1 and smgl-2 are NBAS 
(Neuroblastoma amplified sequence) and DHX34 (DEAH box protein 34) 
respectively61. NBAS and DHX34 form part of an autoregulatory NMD circuit that 
regulates endogenous RNA targets in human cells as well as in D. rerio and C. 
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elegans67. DHX34 is a Superfamily 2 (SF2) DEAH-box RNA helicase. Previous work 
revealed that DHX34 directly interacts with SMG1 and UPF1 forming a complex that 
promotes UPF1 phosphorylation leading to functional NMD68.  
1.1.3   Current working models of NMD  
 
NMD targets mRNAs containing a premature stop codon for rapid degradation. It has 
been recently reported that NMD not only can occur during the first round of 
translation but also can be triggered in the subsequent rounds of translation if the 
mRNA and mRNP features that define a stop codon as a PTC persist69,70. In the NMD 
research field, the critical questions have been “what are defining features that 
distinguish a PTC from normal translation termination codon?” and “when and how 
are NMD machinery assembled to initiate mRNA degradation? ”. Despite lacking of a 
unified model that can explain NMD in all scenarios, currently two different working 
models of NMD have been proposed and widely accepted, the “EJC model” and the 
“faux 3’-UTR model”1,28,71.  
1.1.3.1 The exon junction complex (EJC) model 
 
The EJC model is principally applicable to the NMD mechanism in mammalian cells. 
In mammals, NMD is a pathway that intimately linked with pre-mRNA splicing, which 
deposits the EJC complex 20 to 24 nucleotides upstream of an exon-exon junction. In 
the EJC model, the PTC that elicits efficient NMD needs to situate at least 50-55 
nucleotides upstream the final exon-exon junction, which is the “50 nt rule”72. 
Normally all EJCs will be removed from mRNA by translation machinery after one 
round of translation while in the presence of a PTC that situates more than 50nt 
upstream of exon-exon junction, the EJC stays on mRNA and initiates successive 
events that leads to rapid mRNA degradation. The stalling ribosome on a PTC recruits 
NMD factors to form a so-called SURF complex containing UPF1, a RNA helicase 
and central molecule of NMD and SMG1, a PIKK kinase in its inactive form and its 
two associated factors SMG8 and SMG9, as well as eukaryotic release factor eRF1 and 
eRF3. Subsequently, the RNA helicase DHX34 functions as a bridging molecule and 
promotes the interaction between UPF1 and UPF2-UPF3-EJC complex to form a 
decay-inducing (DECID) complex in the vicinity of PTC, which leads to the 
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phosphorylation of UPF1 by SMG1 kinase and dissociation of eRF1 and eRF3. The 
cycle of phosphorylation and dephosphorylation of UPF1 is critical for NMD 
progression. SMG1 recognizes and phosphorylates serine and threonine residues that 
are next to a glutamine residue (S/TQ motifs), which are enriched at the C-terminal end 
of human UPF1. The phosphorylated UPF1 recruits phospho-binding proteins SMG6 
and SMG5-SMG7 complex for endonucleolytic RNA cleavage and recruiting general 
RNA degradation factors, respectively. SMG6 is an active endonuclease and functions 
as a monomer that cleaves NMD targets in the vicinity of PTC and can interact with 
UPF1 in phospho-dependent and phospho-independent manner. The SMG5 and SMG7 
form a stable heterodimer and bind to phosphorylated UPF1. SMG5-SMG7 complex 
also recruits protein phosphatase 2A (PP2A) and thus play a role in the 
dephosphorylation of UPF1. In addition, previous work shows that SMG5-SMG7 
heterodimer directly recruits the CCR4-NOT deadenylase complex to NMD targets to 
induce the deadenylation-dependent decapping and subsequent RNA degradation. 
Upon the formation of DECID complex, UPF2 interacts with the inhibitory N-terminal 
CH domain of UPF1, induces a large conformational change on UPF1, thereby 
activates UPF1 helicase activity and leads to mRNP remodeling that allows the access 
of nucleases for RNA degradation60. 
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Figure 1.5: The functions of EJC in NMD60 (figure adapted from Ref. 60). a. 
Ribosome stalling at a premature stop codon (PTC) promotes the formation of a so-
called SURF complex containing SMG1-8-9, UPF1, eRF1 and eRF3. An EJC together 
with UPF3 and UPF2 are located downstream of SURF and upstream of a normal 
termination codon. b. Subsequent interaction between UPF1 and UPF2 promotes the 
formation of decay inducing complex (DECID) and leads to the phosphorylation of 
UPF1 by kinase SMG1. c. UPF2 activates UPF1 and leads to mRNP remodeling and 
recruitment of SMG6 for endonucleolytic cleavage of mRNA near the PTC and 
SMG5-SMG7 complex for recruitment of general decay factors.   
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1.1.3.2 Faux 3’-UTR model 
 
Although the EJC-marker model is generally applicable to NMD in mammalian cells, 
the EJC is dispensable for PTC recognition in other eukaryotic organisms such as S. 
cerevisiae, C. elegans, and D. melanogaster45. It was first observed in yeast cells that 
the long 3’-UTR or faux 3’-UTR leads to less efficient ribosome dissociation as 
compared to normal 3’-UTR and triggers NMD73. The faux 3’-UTR model is 
subsequently supported by results in other systems including fly, plant and human 
cells21,74 75. The 3’-UTR is defined by the translation termination codon, which is 
recognized by the ribosome and release factors and the poly (A) tail which is coated by 
poly (A) binding proteins PABPs (PABPC1, PABPC4, and PABPN1). The C-terminal 
part of PABPC1 (Pab1p in S. cerevisiae) can interact with eRF376 77. NMD can be 
inhibited by PABPC1 tethered in proximity downstream of a premature stop codon78 75 
79 suggesting that PABPC1 promotes correct translation termination. In addition, UPF1 
has also been reported to interact with eRFs to form a so-called SURF complex80. The 
competition for binding to eRF3 between PABPC1 and UPF1 is thought to be the 
trigger for long 3’-UTR mediated PTC recognition78 79 81 75. In the case of long 3’-
UTR, the dissociation of ribosome from a PTC might be less efficient caused by UPF1-
mediated inhibition of interaction between eRF3 and PABP. 
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Figure 1.6: PTC recognition in faux 3’-UTR model45 (figure adapted from Ref. 45). 
(a). Normal translation termination is stimulated by the interaction between eRF3 and 
PABP. (b). Aberrant 3’ UTR decreases the efficiency of eRF3 binding to PABP and 
causes the recruitment of UPF proteins to the stalled ribosome to initiate NMD. 
1.1.3.3 Redefinition of NMD 
 
The classical definition of NMD has been changed during the last decade given the fact 
that NMD not only targets PTC-containing mRNAs for degradation but also influences 
the steady-state levels of a significant amount of normal mRNAs or PTC-free mRNAs. 
Thus, based on the current mechanistic models, the emerging point is that (reviewed in 
Ref. 1) NMD can be defined as an mRNA degradation pathway that requires a number 
of well-characterized NMD factors and targets transcripts that fail to terminate 
translation efficiently at their stop codons. The kinetic competition between efficient 
translation termination and the assembly of a degradation-triggering NMD complex 
determines the fate of mRNA1.  
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1.1.4   Regulation of SMG1 kinase activity by SMG8 and SMG9 
 
It is known that phosphorylation is the most common protein post-translation 
modification that plays essential roles in almost all cellular functions. The 
phosphorylation of UPF1 is believed to be the key event and the triggering signal in 
NMD to initiate mRNA degradation. SMG1 is a PIKK kinase that phosphorylates 
UPF1 and its two regulators, SMG8 and SMG9, regulate the kinase activity of SMG1. 
SMG8 and SMG9 interact with SMG1 to form the so-called SMG1C complex27. 
Previous studies using Electron Microscopy (EM) has revealed the 3D molecular 
architecture of human SMG1C complex47. The N-terminal region of SMG1 containing 
HEAT repeats provides the binding platform for SMG8 and SMG9. SMG9 can form a 
complex with SMG1, which requires both N-terminal unstructured region and C-
terminal domain of SMG948. SMG8 is recruited by SMG9 to SMG1 and binding of 
SMG8 to SMG1-SMG9 complex induces large conformational changes, which is 
thought to down-regulate SMG1 kinase activity47.  
 
Figure 1.7: Views of the 3D structure of SMG1C compared with the compatible 
view in SMG1-SMG947 (figure adapted from Ref. 47). Binding of SMG8 to SMG1-
SMG9 complex induces large conformational changes in SMG1. 
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2 The aim of the thesis 
 
Nonsense mediated mRNA decay is a conserved and critical cellular surveillance 
pathway for eukaryotes for the elimination of PTC containing mRNAs to prevent the 
production of C-terminally truncated proteins, the accumulation of which is harmful 
for normal cellular functions and will cause diseases. The mechanism of NMD has 
been extensively investigated for over three decades. Many trans-acting factors 
involved in NMD have been identified by various approaches. In order to understand 
how these NMD players work together to execute and regulate this critical pathway, 
structural characterization of individual NMD proteins as well as complexes formed by 
interacting proteins has been played an important role.  
UPF1 is the most conserved NMD factor in eukaryotes from yeast to humans and it is 
also the central molecule in NMD. The phosphorylation of UPF1 at its C-terminal low-
complexity region is believed to be the definitive step to trigger NMD. SMG1 is a 
PIKK kinase that phosphorylates UPF1 in NMD. It was reported that SMG8 and 
SMG9 are two regulators of SMG1 kinase. Although the electron microscopy studies 
of SMG1-SMG8-SMG9 complex in recent years provided the information for the 
architecture of this complex, the structural basis for the regulation of SMG1 kinase by 
SMG8 and SMG9 is still elusive due to the low resolution structure obtained from 
electron microscope that have been published.  
At the moment, not much is known about SMG8 and SMG9 in terms of their structure 
and functions. Many questions still can be asked such as which family of proteins does 
SMG8 and SMG9 belong to and how SMG8 interacts with SMG9 and how their 
function as regulators of SMG1 kinase is achieved by their structures.  
The aim of this thesis is to characterize the structure and function of SMG8-SMG9 
complex with combined approaches of crystallography, biochemistry and biophysics. 
With the structure of SMG8-SMG9 complex, we could expect to gain insights on the 
mechanism of regulation of SMG1, the kinase that is responsible for UPF1 
phosphorylation.  
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3 Materials  
 
3.1 Cloning and expression strains  
 
Strain/Cell lines Description 
XL1-Blue Electrocompetent bacteria cell for plasmid reproduction.  
BL21 (DE3) Gold pLysS Electrocompetent bacteria cell for protein expression. 
DH10MultiBac Electrocompetent bacteria cell for recombinant bacmid 
production. 
Sf21 Insect cell for recombinant baculovirus production and 
protein expression. 
High Five Insect cell for recombinant protein expression. 
 
3.2 Constructs 
 
Construct Description 
CeSMG8 (1-423) C.elegans SMG8 N-terminal fragment (1-423) in pEC-K-3C-
GST vector 
CeSMG9 (1-385) C.elegans full-length SMG9 in pEC-A-3C-Trx vector 
CeSMG9 (39-385) C.elegans SMG9 C-terminal fragment (39-385) in pEC-A-3C-
Trx vector 
CeSMG9 (60-385) C.elegans SMG9 C-terminal fragment (60-385) in pEC-A-3C-
Trx vector 
CeSMG8 (1-423)/ 
CeSMG9 (39-385) 
C.elegans SMG8 N-terminal fragment (1-423) and C.elegans 
SMG9 C-terminal fragment (39-385) were subcloned in 
MCS1 and MCS2 respectively in pFL vector, SMG8 is C-
terminally his-tagged. 
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CeSMG8 (1-423)/ 
CeSMG9 (59-385) 
C.elegans SMG8 N-terminal fragment (1-423) and C.elegans 
SMG9 C-terminal fragment (59-385) were subcloned in 
MCS1 and MCS2 respectively in pFL vector, SMG8 is C-
terminally his-tagged. 
CeSMG8 (1-423)/ 
CeSMG9 (59-375) 
C.elegans SMG8 N-terminal fragment (1-423) and C.elegans 
SMG9 C-terminal fragment (59-375) were subcloned in 
MCS1 and MCS2 respectively in pFL vector, SMG8 is C-
terminally his-tagged. 
 
3.3 DNA oligonucleotides 
    
       All DNA oligonucleotides were purchased from Sigma-Aldrich and treated as 
recommended by manufacturer. All sequences are given in 5′ -3′ direction.  
 
Oligo name Sequence Oligo ID 
CeSMG9 1FW 3C CCAGGGGCCCGACTCGATGATGAAAAAAGT
GGAAATTCT 
 
oLL40 
CeSMG9 385RV 3C CAGACCGCCACCGACTGCTTAGCTAAAAAA
TTTGTTCGCGT 
 
oLL41 
CeSMG9 385RV ATGCGTCGACTCAGCTAAAAAATTTGTTCG
CGT 
 
oLL48 
CeSMG8 1FW ATGCCCCGGGATGGACATAGCTAAATGGGT 
 
oLL49 
CeSMG8 1FW 3C CCAGGGGCCCGACTCGATGATGGACATAGC
TAAATGGGT 
 
oLL55 
CeSMG8 423RV 3C CAGACCGCCACCGACTGCTTAACGCATATC
GGATTGCCAC 
 
oLL61 
CeSMG9 39FW 3C CCAGGGGCCCGACTCGATGCCGGTGGCCGA
TGACGTGGC 
 
oLL71 
CeSMG9 60FW 3C CCAGGGGCCCGACTCGATGAAGGAGTCTGT
GCGATTTTT 
 
 
oLL72 
 
CeSMG8 423RV ATGCGCTAGCTCAGTGGTGGTGGTGGTGGT
GACGCATATCGGATTGCCAC 
oLL74 
CeSMG9 39FW ATGCGGATCCATGCCGGTGGCCGATGACGT 
 
oLL75 
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CeSMG9 59FW ATGCGGATCCATGAAGGAGTCTGTGCGATT 
 
 
oLL81 
 
CeSMG9 375RV ATGCGTCGACTCAATGGAATCCATTGTCAA
AATG 
 
oLL82 
 
 
3.4 Vectors 
 
Vector name Description 
pEC-K-3C-GST House made, Kanamycin resistance, 3C cleavage site, N-
terminal His-GST tag 
pEC-A-3C-Trx House made, Ampicillin resistance, 3C cleavage site, N-
terminal His-Trx tag 
pFL-deltaSpeI From Imre Berger lab 
 
3.5 Enzymes 
 
Enzyme Source 
Phusion Polymerase Finnzymes 
Taq polymerase MPIB core facility 
T4 DNA Polymerase NEB 
Restriction endonucleases NEB 
T4 DNA Ligase MPIB core facility 
Trypsin, Chymotrypsin, 
Elastase, Glu C, Substilisin 
Roche 
 
3.6 Chemicals and reagents 
 
All common chemicals and reagents were purchased from Sigma-Aldrich, Fluka or 
Hampton unless otherwise stated. 
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3.7 Kits 
 
Kit Supplier 
Qiaquick Gel Extraction Qiagen 
Qiaquick Spin Miniprep Qiagen 
Crystallization screen Kits Hampton Research/Qiagen 
 
3.8 Buffers and Media 
 
 
Media Component 
Luria-Bertani 
(LB) (Miller, 
1972) 
1% (w/v) bacto tryptone 
0.5% (w/v) bacto yeast extract 
170 mM NaCl 
Adjust pH to 7.6 with NaOH 
LB agar plate 1.5 % (w/v) bacto agar in LB 
Antibiotics in respective appropriate concentrations 
SOC Medium 2% (w/v) bacto tryptone 
0.5% (w/v) bacto yeast extract 
10 mM NaCl 
1 mM MgCl2 
2.5 mM KCl 
10 mM MgSO4 
0.4% glucose 
Adjust pH to 7.2 
Terrific Broth 
(TB) 
1.2 % bacto tryptone 
2.4 % bacto yeast extract 
0.4 % glycerol 
ddH2O to 900 ml 
0.017 M KH2PO4 
    0.072 M K2HPO4 
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X-Gal/IPTG LB 
Agar Plates 
 
1.5 % (w/v) bacto agar in LB 
50 µg/ml Kanamycin, 7 µg/ml Gentamycin, 10 µg/ml Tetracyclin 
40 µg/ml X-gal 
0.15 mM IPTG 
Sf-900™ II SFM 
insect cell culture 
medium 
Purchased from company life technologies 
ESF 921 insect 
cell Culture 
medium, protein 
free 
Purchased from company Expression Systems 
 
 
Buffers used for purification and assays are indicated in the Methods in Chapter 4.  
 
 
 
3.9 Equipment 
 
 
Equipment Model Manufacturer 
PCR machine Mastercycler Eppendorf 
Buffer Component 
TBE (20 ×) 1 M Tris 
0.89 M Boric acid 
20 mM EDTA pH 8.0 
SDS-PAGE running buffer (10 ×) 0.25 M Trizma Base 
1.92 M Glycine 
1% SDS 
SDS loading buffer (2 ×) 
 
 
100 mM Tris pH 6.8 
10% β-Mercaptoethanol 
4% SDS 
0.2% Bromophenol Blue 
20% Glycerol 
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Electroporator Gene Pulser/Micro Pulser Bio-Rad 
Electro-cuvette Gene pulser 0.1 cm 
electrode gap 
Bio-Rad 
Bacteria shaker KS-15/Climo-Shaker 
ISF1X 
Kühner 
Cell lysis sonicator Sonifyer VS70T/VS72T Bandelin Electronics 
Insect cell shaker Kuehner shaker Kuehner 
Laminar flow hood Holten LaminAir Thermo electron 
corporation 
Cell viability analyzer Vi-Cell-XR Beckman Coulter 
Dounce homogenizer Borosilicate Glass Fisher Scientific 
Centrifuge Avanti J-20 XP 
Micro centrifuge 5417C & 
5810 
Beckman Coulter 
Eppendorf 
Chromatography columns HisTrap 5 mL 
HiTrap Heparin 5mL 
Mono Q 1mL 
Superdex 200 
HiLoad 200 
GE Healthcare 
 
Chromatography FPLC ÄKTA Purifier GE Healthcare 
Nanodrop 
spectrophotometer 
Nanodrop PeqLab 
Crystallization pipetting 
robot 
Phoenix Art Robbins Instruments 
Crystallization 
visualization system 
Xtal-Focus ExploraNova La Rochelle 
X-ray diffractometer PX scanner 
D8 venture 
Rigaku 
Bruker 
pH meter Lab860  Schott 
Pipettes Eppendorf Research Eppendorf 
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Gel imaging Gel visualization  Roth 
Thermo shaker Thermomixer comfort  Eppendorf 
Vortex mixer Vortex-Genie Scientific Industries 
Fluorescence spectrometer Infinite M1000 Pro Tecan 
 
 
3.10 X-ray sources and synchrotron facility 
 
Crystals were tested with in-house X-ray diffractometer PX-scanner (Rigaku) and D8 
venture (Bruker). Diffraction data sets were collected at Swiss Light Source (SLS) at 
the Paul Scherrer Institute (PSI), Villigen, Switzerland and the Deutsches Elektronen-
Synchrotron (DESY) PETRA III in Hamburg, Germany.  
3.11 Software and web servers 
 
The following software and web servers were used for the data processing and 
analysis, figure generation and thesis writing. 
 
CLC Sequence Viewer (http://www.clcbio.com/products/clc-sequence-viewer/) 
CodonCode Aligner (http://www.codoncode.com/aligner/) 
Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2) 
PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred/) 
UNIPROT (http://www.uniprot.org) 
ProtParam (http://web.expasy.org/cgi-bin/protparam) 
Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/) 
Jalview (http://www.jalview.org/) 
Hampton Research Make-tray tool (http://hamptonresearch.com/make_tray.aspx) 
XDS (http://xds.mpimf-heidelberg.mpg.de) 
SHELX (http://shelx.uni-ac.gwdg.de/SHELX/) 
Phenix (http://www.phenix-online.org) 
Coot (http://www2.mrc-lmb.cam.ac.uk/Personal/pemsley/coot/) 
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Molprobity (http://molprobity.biochem.duke.edu) 
PISA (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html) 
Pymol (http://pymol.org) 
Chimera (http://www.cgl.ucsf.edu/chimera/) 
Origin (www.originlab.com) 
Adobe Illustrator (www.adobe.com/products/illustrator) 
EndNote X7 (http://endnote.com) 
Microsoft Office (www.microsoft.com) 
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4 Methods 
4.1 Cloning 
4.1.1 PCR 
 
DNA sequences of interested were amplified by standard PCR procedure as follows. 
 
Reaction mix (50 µl) 
30 ng template DNA 
1.5 µl Forward primer (10 µM) 
1.5 µl Reverse primer (10 µM) 
1 µl dNTPs (10 mM stock) 
1 µl Phusion polymerase (0.5 u/µl) 
10 µl reaction buffer (5 ×) 
ddH2O 
 
The following cycling conditions were used: 
 
 
Initial denaturation,     95 °C,       5 min,                                                     1 cycle 
 
Denaturation                95 °C,       30 s,             
Annealing                    55 °C,       30 s,                                                       30 cycles 
Extension                     72 °C,       up to DNA length and polymerase  
Final extension            72 °C,       10 min                                                     1 cycle 
 
In some cases, touch down PCR was used, which decreases annealing temperature of 1 
°C per cycle.  
 
4.1.2 Agarose gel electrophoresis 
 
Agarose gel was used to examine PCR amplification and extract the product of 
interest. 1% agarose gel was prepared in 1 × TBE. SYBR Safe stock (Invitrogen) was 
added in 1: 10000 dilutions as dye to the agarose solution for visualization. DNA 
samples were mixed with 6 × loading buffer (Orange Dye, Fermentas) with the volume 
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ratio of 5:1. The electropheris was performed in 1 × TBE buffer. DNA was visualized 
with an UV transilluminator.  
4.1.3 Purification of DNA fragments 
 
PCR products were examined on agarose gels. Bands of interest were cut from the gel 
and purified with the gel extraction kit (Qiagen) following the manufacturer’s protocol.  
The DNA fragments produced by restricted digestion were directly purified with the 
gel extraction kit with the manufacturer’s protocol. All DNA fragments were eluted in 
ddH2O. 
4.1.4 LIC cloning 
 
The ligation independent cloning (LIC) was used for making E. coli expression 
constructs.  
4.1.4.1 Principle 
 
The LIC system utilizes the 3' to 5' exonuclease activity of T4 DNA polymerase to 
generate 12-15 bp overhangs on both the vector and a PCR product. These overhangs 
are long enough to stick together during transformation such that no ligation step 
beforehand is needed. The E. coli machinery repairs nicks during transformation.  
4.1.4.2 Insert processing 
 
PCR products were processed with the following system in a total volume of 20 µl. 
The reaction mix was incubated at room temperature for 30 minutes and the enzyme 
was inactivated at 75 °C for 20 minutes. 
 
Reaction mix 
Gel purified PCR product 600 ng 
T4 DNA Polymerase buffer (10 ×) 2 µl 
dATP (25 mM) 2 µl 
DTT (100 mM) 1 µl 
T4 DNA Polymerase (Novagen) (3u/µl) 0.4 µl 
H2O to 20 µl 
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4.1.4.3 Vector processing 
 
Vectors were first linearized by digestion or by PCR. Digest 2 µg vector with 60 u 
SacII (or 20 u ZraI for 3C LIC vectors) in 100 µl reaction volume, load 250 ng per lane 
of a 0.8% Agarose gel, run at least until slow dye has passed the first half of the gel 
and cut the bands carefully avoiding uncut vector and purify them with the Qiaquick 
purification kit. The linearized vector was further processed by T4 DNA polymerase in 
the presence of dTTP in the following reaction mix. The mix was incubated for 30 
minutes at room temperature and the enzyme was inactivated at 75 °C for 20 minutes.  
 
Reaction mix 
linearized vector 450 ng 
T4 DNA Polymerase buffer (10 ×) 3 µl 
dTTP (25 mM) 3 µl 
DTT (100 mM) 1.5 µl 
T4 DNA Polymerase (Novagen) (3u/µl) 0.6 µl 
H2O to 30 µl 
 
4.1.4.4 Annealing reaction 
 
2 µl of processed insert and 1 µl of processed vector were mixed and incubated for 10 
minutes at room temperature. In next step, 1 µl EDTA (25 mM) was added to the mix 
and incubated for 10 minutes at room temperature. 2 µl of mix was transformed in 
competent E. coli.  
4.1.5 Restriction digest and ligation 
 
Cloning of constructs for insect cell expression was done by using classical restriction 
digest and ligation. DNA fragments from PCR and vectors were digested by 
appropriate restriction endonucleases (NEB) in a system of 20 µl.  1 µg of PCR product 
or vector and 0.5 µl of each enzyme (20 u/µl) together with 2 µl of appropriate NEB 
reaction buffer (10 ×) were added to the reaction mix. The digestion was carried out at 
37 °C for 5 hours. The products of digestion were purified with Qiaquick Gel 
Extraction kit (Qiagen). The insert and linearized vector were further ligated in 15-µl 
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reaction system containing 1 µl of T4 DNA ligase (400 u/µl), 1.5 µl of T4 DNA ligase 
buffer (10 ×), 11 µl of insert and 1.5 µl of linearized vector. The ligation reaction was 
performed at room temperature for 2 hours.  
4.1.6 Transformation 
 
Appropriate amount of plasmid or ligation product were added to the thawed electro-
competent cells (50 µl) on ice and transformed using the electroporation method. Cells 
were transferred to 0.1 cm electroporation cuvette and an electrical pulse of 1.8 kV was 
applied. Cell suspension was mixed with 200 µl SOC medium and then transferred to a 
1.5 ml-eppendorf tube and incubated in a thermomixer at 37 °C for 50 min, 1000 rpm. 
Cells were then plated on a LB agar plate with appropriate antibiotics and incubated 
overnight at 37 °C.  
4.1.7 Plasmid purification 
 
In order to extract recombinant plasmids, single colony was picked from LB agar plate 
and inoculated into 5 ml LB culture with appropriate antibiotics. The culture was 
shaken in a shaker at 37 °C overnight with the speed of 220 rpm. Bacteria cells were 
pelleted by centrifugation with 4000 rpm for 10 minutes. Plasmids were purified with 
Qiaquick Miniprep kit and eluted in ddH2O in a volume of 50 µl. The concentration of 
plasmid was measured with the Nanodrop spectrophotometer.  
4.1.8 DNA sequencing 
               
DNA sequencing was done in the core facility of Max Planck Institute of Biochemistry 
or in the company Eurofins.      
4.2 Expression of recombinant proteins 
 
Recombinant proteins were expressed in both E. coli and insect cells with different 
procedures.  
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4.2.1 Expression of recombinant proteins in E. coli 
              
Proteins were either singly expressed or co-expressed by the means of co-
transformation in BL21 (DE3) Gold pLysS under the control of T7 bacteriophage 
transcription. Cells were grown in TB medium with appropriate antibiotics at 37 °C 
with constant shaking at the speed of 220 rpm. After the cell density OD600 reached 
between 1 and 2, the temperature was reduced to 18 °C and 0.3 mM IPTG was added 
to the culture to induce protein expression. Cells were harvested approximately 16 
hours post-induction by centrifugation (6000 rpm, 10 minutes). The cell pellets were 
either immediately lysed for purification or frozen with liquid nitrogen and stored at -
80 °C.  
4.2.2 Expression of recombinant proteins in insect cell     
      
C. elegans SMG8 and SMG9 were subcloned in MCS1 (multiple cloning site 1) and 
MCS2 (multiple cloning site 2) respectively in the same pFL vector for co-expression. 
The recombinant plasmid was then transformed into DH10MultiBac competent cell 
and the recombinant Bacmid was selected with blue-white screening method. Insect 
cells sf21 and High Five were used for virus production and protein expression 
respectively.  
4.2.2.1 Blue-white screen 
Generally 300 ng of the recombinant plasmid was transformed in 50 µl of 
DH10MultiBac competent cell with electroporation method. The transformed cell 
suspension was mixed with 800 µl of SOC medium and incubated at 37 °C with 
constant shaking at 1000 rpm in a thermomixer for 4 hours. Appropriate volume of cell 
suspension (generally 100 µl) was plated on a X-Gal/IPTG LB Agar plates. The plates 
were placed at 37 °C for 48 hours. Single white colony containing composite Multibac 
DNA was picked and inoculated into 2 ml of LB culture containing Kanamycin and 
Gentamycin for overnight growth at 37 °C.  
4.2.2.2 Bacmid isolation 
 
Bacmid DNA was isolated by alkaline lysis, using the Qiaprep Spin Miniprep kit with 
the following protocol: 
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a. Resuspend cell pellet in 250 µl Buffer P1 and transfer to a microcentrifuge tube. 
b. Add 250 µl Buffer P2 and mix thoroughly by inverting the tube 4-6 times. 
c. Add 350 µl Buffer P3 and mix by inverting. 
d. Centrifuge for 10 min at maximum speed (e.g. 16.100 × g). Transfer supernatant to a 
fresh tube.  
e. Repeat step d to remove all residual precipitation. 
f. Add 800 µl iso-propanol, invert tube a few times to mix and place on ice for 10 min 
to precipitate DNA. 
g. Centrifuge sample for 15 min at maximum speed at room temperature. 
h. Locate the DNA pellet and carefully remove supernatant without disturbing the 
pellet. Add 70% ethanol and invert the tube several times to wash the pellet. 
i. Centrifuge for 5 min at maximum speed at room temperature.  
j. Remove as much supernatant as possible. Air-dry pellet for 5-10 min in a sterile 
environment (e.g. in a Petri dish). 
k. Dissolve DNA pellet in 40 µl sterile H2O by gently tapping the bottom of the 
centrifuge tube. Measure concentration after 10 min. 
4.2.2.3 Transfection   
 
The isolated bacmid DNA was then transfected into Sf21 cells to generate P1 virus 
(initial virus) with the following protocol: 
a. For every bacmid DNA, put 2 ml 0.8 × 106 freshly diluted Sf21 cells in two wells 
each of a 6-well tissue culture plate and incubate for 30 min at 27 °C. 
b. Gently mix 1 µg bacmid DNA with 8 µl PEI transfection agent (1 mg/ml aqueous 
solution, sterile filtered) in 200 µl of serum free medium (e.g. Sf-900 II SFM). 
Incubate for 15 min at 27 °C. 
c. Add bacmid mix drop by drop to wells with adherent cells in 6-well plate. Seal plate 
with lid or parafilm and incubate at 27 °C.  
d. After 3-5 days, harvest virus-containing supernatant by aspirating with a pipet and 
store in 15 ml Falcon tubes at 4 °C, protected from light.  
4.2.2.4 Virus amplification 
P1 virus produced from transfection was amplified to higher titer P2 and P3 virus for 
protein expression with the following protocol.  
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a. Add 1 ml P1 virus to 25 ml freshly diluted Sf21 cells at 0.5 × 106 cells/ml in a 250 
ml shaker flask. Incubate cells on the shaker (80 rpm) at 27 °C.  
b. After 48 hours, monitor cell count. Cells should have doubled approximately and 
started to swell. Split to below 1 × 106. 
c. After additional 48 hours, collect supernatant and store at 4 °C in the dark. This is P2 
virus. 
d. Add 0.1 % (v/v) of P2 virus to 200 – 500 ml freshly diluted Sf21 cells at 0.5  × 106 
cells/ml in a 2 L shaker flask (Fernbach type). Incubate cells on the shaker (80 rpm) at 
27 °C and continue as in step b and c. This is P3 virus. 
4.2.2.5 Large-scale expression 
 
Appropriate amount of P3 virus (based on small scale expression test) was added to 
freshly diluted 500 ml High-Five cells at 1 × 106 cell/ml in each 2 L shaker flask. 
Incubate cells on the shaker (80 rpm) at 27 °C. After 72 hours, harvest cells by 
centrifugation (2000 rpm, 20 min).  
4.2.2.6 Expression of selenium - methionine derivatized protein 
In order to express selenium-methionine derivatized protein, normal medium and ESF 
921 medium (purchased from Expression System) were mixed at the ratio of 2: 1 in a 
total volume of 300 ml to adapt High-Five cells. After 72 hours, cells were diluted to 
0.5 × 106 cell/ml in 600 ml ESF 921 medium (300 ml in each flask). After additional 72 
hours, combine two flasks and count cell density. Cells were diluted to 1 × 106 cell/ml 
in 500 ml ESF 921 medium in each of 6 flasks and cells were infected with P3 virus. 
L-selenium-methionine was added to cell culture at a final concentration of 0.1 mg/ml 
at three time points (18, 25, 45 hours) after infection. Cells were harvested 60 hours 
post-infection.  
 
 
 
 
 
 
4 Methods  
	  44	  
4.3 Purification of recombinant proteins 
 
4.3.1 Purification of C. elegans full-length SMG9 (1-385)      
 
Bacterial pellets from 1 L TB cell culture were resuspended in lysis buffer containing 
50 mM Tris PH 8.0, 300 mM NaCl, 10% Glycerol and 25mM imidazole. Cells were 
lysed by sonication for 10 min (40% amplitude, 0.5s on/0.5s off). Supernatant was 
collected after centrifugation at 25,000 rpm for 45 min at 10 °C and filtered using 5 µm 
filter (Merck Millipore). The supernatant was loaded into a 5 ml HisTrap Ni-NTA 
column pre-equilibrated with 5-column volume of lysis buffer. The column was then 
washed with 250 ml washing buffer containing same ingredients as in lysis buffer. 
Protein was eluted with 45 ml elution buffer containing 50 mM Tris PH 8.0, 300 mM 
NaCl, 10% Glycerol, and 500 mM imidazole. The eluate was added with his-tagged 3C 
protease (1 ml, 1 mg/ml in stock) and subjected to dialysis overnight in 2 L dialysis 
buffer containing 50 mM Tris PH 8.0, 100 mM NaCl, 10% Glycerol. The protein 
solution after dialysis was reloaded into Ni-NTA column pre-equilibrated with dialysis 
buffer to remove cleaved his-Trx tag. The flow-through from this step was collected 
and loaded into mono Q column on ÄKTA purifier system and run ion-exchange 
chromatography with Buffer A containing 50 mM Tris PH 8.0, 100 mM NaCl, 10% 
Glycerol and buffer B containing 50 mM Tris PH 8.0, 1 M NaCl, 10% Glycerol. The 
protein of interest was purer in flow-through than in eluted fractions. The flow-through 
was concentrated and subjected to gel-filtration chromatography with gel-filtration 
buffer containing 50 mM Tris PH 8.0, 150 mM NaCl, 10% Glycerol on ÄKTA purifier 
system. 
4.3.2 Purification of C. elegans SMG9 C-terminal fragment (39-385)     
 
The expression and purification of C. elegans SMG9 C-terminal fragment (39-385) 
followed same protocol as for C. elegans full-length SMG9 (1-385), except in the 
purification of CeSMG9 (39-385), the flow-through from mono Q was reloaded to the 
same mono Q column (equilibrated with buffer A) again to remove impurities. The 
flow-through from second mono Q run was concentrated and subjected to gel-filtration 
chromatography with gel-filtration buffer containing 50 mM Tris PH 8.0, 300 mM 
NaCl, 10% Glycerol.  
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4.3.3 Purification of C. elegans SMG9 C-terminal fragment (59-385)        
 
The expression and purification of CeSMG9 (59-385) followed same protocol as for C. 
elegans full-length SMG9 (1-385), except in the purification of CeSMG9 (59-385), 
instead of the flow-through, the fractions of peak from mono Q were concentrated and 
subjected to gel-filtration chromatography.  
4.3.4 Purification of C. elegans SMG8 N-terminal fragment (1-423) in 
complex with C. elegans SMG9-FL  
 
N-terminal his-GST tagged CeSMG8 (1-423) and N-terminal his-Trx tagged CeSMG9-
FL were co-transformed in BL21 (DE3) Gold pLysS and expressed in 4 liters of TB 
cell culture. Cells were lysed with previously described protocol in lysis buffer 
containing 50 mM Tris PH 8.0, 300 mM NaCl, 10% Glycerol. The supernatant was 
loaded on a gravity-flow column manually packed with 5ml Glutathione Sepharose 
resins. The column was then washed with 20-column-volume lysis buffer and eluted 
with 45 ml elution buffer containing 50 mM Tris PH 8.0, 300 mM NaCl, 10% 
Glycerol, 20 mM GSH. The eluate was added with his-tagged 3C protease (1ml, 1 
mg/ml in stock) and subjected to dialysis overnight in 2 L dialysis buffer containing 20 
mM Tris PH 8.0, 100 mM NaCl, 10% Glycerol. The protein solution was then loaded 
on mono Q column to run ion-exchange chromatography with buffer A containing 50 
mM Tris PH 8.0, 100 mM NaCl, 10% Glycerol and buffer B containing 50 mM Tris 
PH 8.0, 1 M NaCl, 10% Glycerol. The fractions of peak were then concentrated and 
subjected to gel-filtration chromatography with gel-filtration buffer containing 20 mM 
Tris PH 8.0, 150 mM NaCl.  
4.3.5 Purification of C. elegans SMG8 N-terminal fragment (1-423) in 
complex with C. elegans SMG9 C-terminal fragment (39-385)  
 
Insect cell pellets from 1 L cell culture were resuspended with lysis buffer containing 
20 mM Tris PH 8.0, 150 mM NaCl and 20 mM imidazole. Cells were lysed with 
Dounce homogenizer on ice. The lysate was centrifuged at 4000 rpm for 15 minutes. 
The supernatant was then centrifuged at 25,000 rpm for 1 hour. The supernatant from 
this step was filtered with a 5 µm filter and then loaded to Ni-NTA column pre-
equilibrated with 5-column-volumn washing buffer containing 50 mM Tris PH 8.0, 
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300 mM NaCl, 10% glycerol and 25 mM imidazole. The column was then washed 
with 200 ml washing buffer. Proteins were eluted with 40 ml elution buffer containing 
20 mM Tris PH 8.5, 100 mM NaCl and 400 mM imidazole. The eluate was loaded to 
mono Q to run ion-exchange chromatography with buffer A containing 20 mM Tris PH 
8.5, 100 mM NaCl and buffer B containing 20 mM Tris PH 8.5, 1 M NaCl. The flow-
through and eluted fractions from mono Q were collected and subjected to gel-
filtration chromatography with gel-filtration buffer containing 10 mM Hepes pH 7.2, 
150 mM NaCl. 
4.3.6 Purification of C. elegans SMG8 N-terminal fragment (1-423) in 
complex with C. elegans SMG9 C-terminal fragment (59-385)         
 
The expression and purification of C. elegans SMG8 (1-423) in complex with C. 
elegans SMG9 (59-385) followed the same protocol as for the complex of C. elegans 
SMG8 (1-423) and C. elegans SMG9 (39-385) as described in 4.3.5.  
4.3.7 Purification of C. elegans SMG8 N-terminal fragment (1-423) in 
complex with C. elegans SMG9 C-terminal fragment (59-375)                            
 
Insect cell pellets from 3 liters of cell culture were resuspended with lysis buffer 
containing 25 mM Tris PH 8.0, 300 mM NaCl and 20 mM imidazole. Cells were lysed 
with Dounce homogenizer on ice. The lysate was centrifuged at 4000 rpm for 15 
minutes. The supernatant was then centrifuged at 25,000 rpm for 1 hour. The 
supernatant from this step was filtered with a 5 µm filter and then loaded to Ni-NTA 
column pre-equilibrated with 5-column-volumn washing buffer containing 25 mM Tris 
PH 8.0, 300 mM NaCl and 25 mM imidazole. The column was then washed with 200 
ml washing buffer. Proteins were eluted with 45 ml elution buffer containing 25 mM 
Tris PH 8.0, 300 mM NaCl and 400 mM imidazole. The eluate was dialyzed in buffer 
containing 20 mM Tris PH 8.0, 100 mM NaCl overnight at 4 °C. The protein solution 
was then loaded on a 5 mL HiTrap Heparin column for ion-exchange chromatography 
with buffer A containing 20 mM Tris PH 7.5, 100 mM NaCl and buffer B containing 
20 mM Tris PH 7.5, 1 M NaCl.  The flow-through and pure fractions from Heparin run 
were collected and subjected to gel-filtration chromatography with buffer containing 
25 mM Tris PH 8.0, 300 mM NaCl and 2 mM DTT. 
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4.3.8 Purification of selenium-methionine derivatized C. elegans 
SMG8 (1-423) in complex with C. elegans SMG9 (59-375)            
 
The purification protocol for selenium-methionine derivatized C. elegans SMG8 (1-
423) in complex with C. elegans SMG9 (59-375) was same as described in 4.3.7, 
except 4 mM β-ME was added in lysis buffer and buffers for Ni-affinity purification 
and 2 mM DTT was added to buffers for subsequent purification steps. All buffers 
were degased.  
4.4 SDS-PAGE 
 
SDS-PAGE was used to examine the purity of protein of interest. 12.5% and 15% 
SDS-gel were made with following recipe.  
 
Reagent 5% Stacking gel 
(ml) 
12.5% Resolving 
gel  (ml) 
15% Resolving      
gel  (ml) 
0.5 M Tris pH 6.8 1.26   
1.5 M Tris pH 8.8  2.5 2.5 
30% Acrylamide/ 
methylene-bisacrylamide 
(37.5:1) 
0.83 4.17 5 
H2O 2.75 3.12 2.29 
10% SDS 0.05 0.1 0.1 
10% APS 0.1 0.1 0.1 
TEMED 0.01 0.01 0.01 
 
The SDS-PAGE was run in 1 × SDS running buffer. Samples were mixed with loading 
buffer and loaded to gel wells. 100 V was applied until the running front reached 
resolving gel and 220 V was applied until the running front reached the bottom of gel. 
Gels were stained by Coomassie staining.  
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4.5 Measurement of protein concentration 	  
Nanodrop spectrophotometer was used to measure the UV absorbance of protein at 280 
nm. Extinction coefficient was calculated with ProtParam. Given the path length as 1 
cm, the protein concentration was calculated as: protein concentration (mg/ml) = A280 
(mg/ml)/extinction coefficient.  
4.6 Limited proteolysis 
 
Proteases Trypsin, Elastase, Chymotypsin, GluC and Subtilisin were prepared in 1: 10, 
1: 100, 1: 1000 dilutions (stocks at 1 mg/ml) with buffer containing 20 mM Hepes pH 
7.5, 50 mM NaCl, 10 mM MgSO4. For each reaction, 10 µl of protein (0.6 mg/ml) was 
mixed with 3 µl of diluted protease and incubated on ice for 30 minutes. 1 µl AEBSF 
(100 mM) was used to stop the reaction. The sample was added with 5 µl 3 × SDS-
loading buffer and boiled for 5 minutes at 95 °C and loaded on SDS-gel. For time 
course proteolysis, 10 µl of protein substrate (0.6 mg/ml) was incubated with 3 µl of a 
particular protease at a fixed concentration for different amount of time.  
4.7 Mass spectrometry 	  
The protein total mass measurement and peptide fingerprint analysis were done in the 
MPIB core facility. 
4.8 Protein storage 	  
Proteins for long-term storage were flash frozen in liquid nitrogen and stored at -80 °C 
in freezer.  
4.9 Crystallization and structure determination  
4.9.1 Crystallization 
 
Optimized native crystals of CeSMG8 (1-423)/CeSMG9 (59-375) complex were 
obtained at 10 °C by hanging drop vapor diffusion within 1 day in drops formed by 
equal volumes (1.5 µl) of protein (6.8 mg/ml in gel filtration buffer 25 mM Tris, 300 
mM NaCl, pH 8.0 mixed with 0.11 mM YCl3) and crystallization buffer (10% 
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PEG3350, 0.1 M Tris pH 8.5). Crystals were cryoprotected with crystallization buffer 
supplemented with 25% ethylene glycol prior to cryo-cooling and data collection. 
Selenium-methionine derivatized crystals of CeSMG8 (1-423)/CeSMG9 (59-375) were 
obtained at 10 °C by hanging drop vapor diffusion within 1 day in drops formed by 
equal volumes (1.5 µl) of protein (6.7 mg/ml in gel filtration buffer 25 mM Tris, 300 
mM NaCl, pH 8.0, 2 mM DTT mixed with 0.11 mM YCl3 and 2 mM TCEP) and 
crystallization buffer (11% PEG3350, 0.1 M Tris pH 8.5). In order to increase the size 
of selenium-methionine derivatized crystal and boost the anomalous signal, 1 mL 
paraffin oil was added on top of the reservoir buffer (0.7 mL). Crystals were 
cryoproteced with crystallization buffer supplemented with 25% ethylene glycol and 5 
mM TCEP prior to cryo-cooling and data collection.                   
4.9.2 Crystal soaking with nucleotides 
 
Native crystals were soaked for 10 minutes in cryoprotectant supplemented with 10 
mM GDP and for 30 minutes in cryoprotectant supplemented with 10 mM ADP prior 
to cryo-cooling and data collection.             
4.9.3 Data collection 
  
All diffraction data were collected at 100K at the Swiss Light Source (SLS) beamline 
PXII, except diffraction data for ADP-soaked crystals were collected at the Deutsches 
Elektronen-Synchrotron (DESY) PETRA III beamline P11. The selenium-methionine 
derivatized crystals were measured at the peak wavelength of the selenium at 0.979 Å. 
The GDP and ADP-soaked crystals were measured at the wavelength of 0.9785 Å and 
1.2547 Å, respectively.  
4.9.4 Structure determination and refinement            	  
The data were processed and scaled with XDS82. The crystals belong to trigonal space 
group P3221 with 3 copies of the complex in 3 fold NCS per asymmetric unit.  
SHELX83 was used for phasing and phenix.autobuild84 was used for initial automatic 
model building. The best built copies of SMG8 and SMG9 were chosen from initial 
selenium-methionine derivatized model and used as search models for molecular 
replacement with Phaser85. The model was completed with iterative rounds of manual 
building in Coot86 and refinement with phenix.refine87.  
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The GDP bound SMG8-9 structure was solved by molecular replacement with Phaser 
using selenium-methionine derivatized SMG8 and SMG9 structures as search models.  
The ADP bound SMG8-9 structure was solved by molecular replacement with Phaser 
using SMG8 and SMG9 structures from SMG8-9-GDP model as search models. The 
models were completed with Coot and refined with phenix.refine. The data processing 
and refinement statistics are summarized in Table 1 in supplementary material.  
4.10 Nucleotides binding experiment 
 
The affinities for nucleotides were determined by fluorescence measurements on an 
Infinite M1000 Pro (Tecan). Experiments were carried out at 21 °C in a buffer 
containing 25 mM Tris pH 8.5, 150 mM NaCl, and 5 mM MgCl2. Increasing protein 
concentrations were incubated with 1.67 µM of methylanthraniloyl (mant) labeled 
nucleotides for 30 minutes at room temperature. Fluorescence of mant-nucleotides was 
excited at 355 nm and emission spectra were then monitored from 400 to 500 nm, with 
emission maxima detected at 448 nm. The intrinsic protein fluorescence as well as the 
mant-nucleotide background was subtracted from the curves. Curve fitting and 
dissociation constant (Kd) were done using Origin. Curves were done in triplicate. 
4.11 Sequence alignments 
 
The multiple sequence alignments of SMG8 and SMG9 were generated using program 
Clustal Omega88 and edited in Jalview89. 
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5 Results  	  
5.1 Domain organization of SMG8 and SMG9 
 
SMG8 and SMG9 from both humans and C. elegans have been investigated in this 
project. The domain architectures of SMG8 and SMG9 have not been well 
characterized since they were identified as two interacting partners of SMG1. 
Sequence alignments and disordered region prediction (supplementary materials) 
revealed that SMG8 in both human and C. elegans contain two conserved and 
structured regions, a N-terminal large region and a C-terminal small region connected 
by a large disordered region. SMG9 in both human and C. elegans were predicted to 
contain a N-terminal disordered region and a C-terminal putative NTPase domain. The 
accurate domain boundaries have not been defined in the absence of detailed structural 
information. In this thesis, C. elegans SMG8 and SMG9 were used as subjects for 
structural characterization with X-ray crystallography as they are smaller and contain 
less disordered regions compared to their human orthologues, which are advantages for 
crystallization. Various constructs of CeSMG9 were either expressed and purified 
singly or co-expressed and purified with N-terminal fragment of CeSMG8 for 
crystallization.  
 
Figure 5.1: Domain organization of SMG8 and SMG9 in humans and C. elegans. 
The SMG8 N-terminal domain is shown in orange and C-terminal domain is shown in 
grey. The SMG9 C-terminal NTPase domain is shown in blue. The disordered regions 
are shown as lines.  
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5.2 Purification of full-length C. elegans SMG9 
 
The full-length (FL) CeSMG9 (1-385) was the first construct purified. Expression and 
purification procedures were described in Methods 4.3.1. CeSMG9-FL was eluted as a 
single peak on a Superdex 200 gel filtration column. The elution volume of peak 
suggests that CeSMG9-FL exists as a monomer in the solution. Fractions of peak were 
collected and examined with SDS-PAGE. Although the protein was pure, apparent 
degradation was observed on the gel. The degradation probably occurred at the N-
terminal disordered region of CeSMG9.  
 
Figure 5.2: Gel filtration chromatography of CeSMG9-FL and SDS-PAGE. (a). C. 
elegans full-length SMG9 was eluted as a single peak from a superdex 200 column. 
The elution volume of peak was 14.62 ml as indicated on top of the peak. (b). 12.5% 
SDS-PAGE of selected fractions of gel filtration chromatography shown in (a).     
5.3 Limited proteolysis of CeSMG9-FL 
 
In order to obtain a structural core of CeSMG9 for crystallization, limited proteolysis 
of CeSMG9-FL was performed with Trypsin, Elastase, Chymotrypsin, GluC and 
Subtilisin with protocol described in Methods 4.6. With Trypsin digestion, significant 
bands were observed on the SDS-gel. A time course proteolysis with trypsin was 
subsequently performed to obtain stable fragments. The bands of interest as well as a 
negative control were extracted from the gel and analyzed by peptide mass 
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fingerprinting to identify the boundary of each fragment. The results are shown in the 
figure below. The band No.4 is the full-length CeSMG9 used as the negative control, 
the band No.3 is the fragment consisting of residues from 39 to 385, the band No.2 is 
the fragment consisting of residues from 171 to 385 and the band No.1 can’t be 
identified due to weak intensity.  
 
Figure 5.3: Limited proteolysis of CeSMG9-FL. (a). Trypsin, Elastase, 
Chymotrypsin, GluC and Subtilisin were used to digest protein CeSMG9-FL. Each 
enzyme was diluted to three different working concentrations and incubated with 
protein substrate for the same time (30 minutes). M: Marker; NC: negative control. (b). 
Protein CeSMG9-FL was incubated with Trypsin (0.01 mg/ml) for 0.5 hour, 1 hour, 
1.5 hours, 2 hours, 4 hours and 6 hours. Samples were examined with 12.5% SDS-
PAGE. Bands extracted for peptide mass spectrometry analysis were labeled with 
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numbered red rectangles.  Results are shown at the right of the gel.  
5.4 Purification of CeSMG9 C-terminal fragment (39-385) 
 
Based on the result of limited proteolysis of CeSMG9-FL, a new construct CeSMG9 
(39-385) was expressed and purified with the protocol described in Methods 4.3.2. 
CeSMG9 (39-385) was eluted in a homogenous peak in gel filtration chromatography. 
Fractions of peak were examined on SDS-PAGE gel and no degradation was observed 
on the gel. However, although the protein was pure and homogenous, no crystal hits 
were obtained from crystallization screening.  
 
Figure 5.4: Purification of CeSMG9 (39-385) and SDS-PAGE. (a). Gel filtration 
chromatography on a Hiload 75 column. Blue line represents the absorption at 280 nm; 
red line represents the absorption at 260 nm. (b). 12.5% SDS-PAGE of selected 
fractions of gel filtration chromatography shown in (a).  
5.5 Purification of CeSMG9 C-terminal fragment (59-385) 
 
The CeSMG9 was further N-terminally truncated to a shorter construct containing 
residues from 59 to 385 based on secondary structure prediction and sequence 
conservation. CeSMG9 (59-385) was expressed and purified with the protocol as 
described in Methods 4.3.3. The protein was pure as shown on the SDS-gel, however, 
it’s not homogenous as indicated by the profile of peak in gel filtration 
chromatography. No crystal hits were found by crystallization screening.  
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Figure 5.5: Purification of CeSMG9 (59-385). (a). Gel filtration chromatography on 
a superdex 200 column. Blue line represents the absorption at 280 nm; red line 
represents the absorption at 260 nm. (b). 12.5% SDS-PAGE of fractions of peak of gel 
filtration chromatography shown in (a).  
5.6 Co-expression and purification of CeSMG8 N-terminal 
fragment (1-423) and CeSMG9-FL 
 
Based on secondary structure prediction, the N-terminal 423 amino acids of CeSMG8 
is likely the region that corresponds to a folded domain. Unlike CeSMG9, CeSMG8 (1-
423) is not soluble when it is singly expressed in E. coli. Therefore, to test whether this 
N-terminal region of CeSMG8 is sufficient to bind CeSMG9, the plasmids of 
constructs of CeSMG8 (1-423) and CeSMG9-FL were co-transformed to the 
competent cell and co-expressed in E. coli. The expression and purification procedures 
were described previously in Methods 4.3.4. The results of gel filtration 
chromatography and SDS-PAGE gel shown below indicate that CeSMG8 (1-423) can 
be stabilized by CeSMG9 during co-expression and is sufficient to bind the full-length 
CeSMG9.  
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Figure 5.6: Purification of CeSMG8 (1-423) in complex with CeSMG9-FL. (a). Gel 
filtration chromatography on an analytical superdex 200 column. (b). 12.5% SDS-
PAGE of fractions of peak from gel filtration chromatography shown in (a).  
5.7 Co-expression and purification of CeSMG8 N-terminal 
fragment (1-423) and CeSMG9 C-terminal fragment (39-385) 
 
Although the complex of CeSMG8 (1-423) and CeSMG9-FL can be expressed and 
purified from E. coli, the yield was very low (approximately 30 µg protein in total can 
be purified from 6 liters of E. coli culture). Therefore, expression of this complex in 
insect cells was necessary to obtain higher yield of protein for crystallization. The 
second problem was that CeSMG9-FL degraded also in complex with CeSMG8 (1-
423) after staying in fridge at 4 °C for overnight. Based on previous results that the 
degradation of CeSMG9 occurs at its N-terminal unstructured region, a shorter 
construct CeSMG9 (39-385) was co-expressed with CeSMG8 (1-423) in insect cells. 
The expression and purification procedures were described in Methods 4.3.5. The 
protein yield from insect cells expression was much higher than expression in E. coli 
(shown in Figure 5.7 (a) and (b)) and the N-terminally truncated CeSMG9 is still 
sufficient to bind CeSMG8 (1-423) (shown in Figure 5.7 (c) and (d)).  
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Figure 5.7: Purification of CeSMG8 (1-423) in complex with CeSMG9 (39-385). 
(a). Gel filtration chromatography on a superdex hiload-75 column. (b). 12.5% SDS-
PAGE of fractions of peak from gel filtration chromatography shown in (a). CeSMG8 
(1-423) and CeSMG9 (39-385) were not well separated on the gel. (c). Overlay of 
profiles of gel filtration chromatography of CeSMG9 (39-385) alone and in complex 
with CeSMG8 (1-423). Both gel filtration run were carried out on the same superdex 
200 column. (d). Fractions of each peak were examined on a precast 4% -12% gradient 
SDS-PAGE gel. The molecular weight for each marker band from top to bottom is 116 
kDa, 66 kDa, 45 kDa, 35 kDa, 25 kDa, 18 kDa and 14 kDa.  
5.8 Crystallization of complex CeSMG8 (1-423)/CeSMG9 
(39-385) 
 
Purified CeSMG8 (1-423)/CeSMG9 (39-385) complex was used for crystallization 
screening. Small crystals shown in Figure 5.8 (a) were obtained within 1 day with 
sitting drop method in initial screening. The crystals could be reproduced shown in 
Figure 5.8 (b) with hanging drop method in a 24-well plate by changing the 
concentration of protein or precipitant. However, those crystals were very small, 
fragile and diffracted only to around 7 Å. In order to increase the crystal size and 
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improve the resolution, repeated seeding was carried out in sitting drops and the crystal 
after optimization shown in Figure 5.8 (c) can diffract to 3.1 Å. However, data analysis 
with phenix.xtriage90 (Figure 5.8, d) indicated that the crystal had problem of perfect 
twinning, which became the main challenge for the structure determination.  
 
  (d) 
Results of the twinning test with phenix.xtriage 
For acentric data 
<I2>/<I>2: 1.470  (untwinned: 2.0, perfect twin: 1.5) 
<F>2/<F2>: 0.902  (untwinned: 0.785, perfect twin: 0.885) 
<|E2-1|>: 0.514  (untwinned: 0.736, perfect twin: 0.541) 
Multivariate Z score L-test: 34.175  (lower than 3.5 for good to reasonable data) 
 
Figure 5.8: Crystals of complex CeSMG8 (1-423)/CeSMG9 (39-385). (a). Crystals 
from initial screening grew at 10 °C in the condition of 18% PEG 4000, 0.1M Tris-Cl, 
pH 8.0 in a sitting drop containing 150 nl protein (12 mg/ml) and 150 nl crystallization 
buffer. (b). Crystals were reproduced at 10°C in the condition of 10% PEG 4000, 0.1M 
Tris-Cl, pH 8.0 in a hanging drop containing 1 µl protein (12 mg/ml) and 1 µl 
crystallization buffer. (c). Crystal was optimized with repeated seeding and grew at 
10°C in the condition of 18% PEG4000, 0.1M Tris-Cl, pH 8.0 in a sitting drop 
containing 200 nl protein (11 mg/ml), 200 nl crystallization buffer and 50 nl seeds. (d). 
Results of the twinning test with phenix.xtriage. Both Wilson ratios and moments are 
close to the values of perfect twin. The large Z score of L-test also indicates twinning. 
The methods of twinning test are well documented in the tutorial of phenix.xtriage. 
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5.9 Co-expression and purification of complex CeSMG8 (1-
423)/CeSMG9 (59-385) 	  
In order to improve the quality of crystals, the shorter construct CeSMG9 (59-385) was 
used to form the complex with CeSMG8 (1-423). Both proteins were co-expressed in 
insect cells and purified with procedures described previously in Methods 4.3.6. The 
results of gel filtration chromatography and SDS-PAGE shown in figure 5.9 indicate 
that this shorter construct CeSMG9 (59-385) is sufficient to interact with CeSMG8 (1-
423). However, two bands were observed at the position of CeSMG9 on the gel due to 
possible degradation. The profile of peak of gel filtration chromatography also showed 
the inhomogeneity of the protein, which could be caused by the degradation. 	  	  
	  	  
Figure 5.9: Purification of complex CeSMG8 (1-423/CeSMG9 (59-385). (a). Gel 
filtration chromatography on a superdex 200 column. (b). 12.5% SDS-PAGE of 
fractions of peak of gel filtration chromatography shown in (a).  
5.9.1 Identification of degradation boundary by Mass Spectrometry 	  
In order to know the degradation boundary of CeSMG9 (59-385), purified protein of 
complex CeSMG8 (1-423)/CeSMG9 (59-385) was sent to Mass Spectrometry analysis. 
The molecular weight of two CeSMG9 fragments shown in figure 5.10 indicates that 
the degradation probably occurred at the C-terminus of CeSMG9 and the shorter 
fragment is CeSMG9 (59-375) based on the calculation of its theoretical molecular 
weight. 
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Figure 5.10: Molecular weight of CeSMG9 fragments measured by Mass 
Spectrometry. The boundaries of CeSMG9 fragments were marked on top of each 
peak.  
5.10 Co-expression and purification of complex CeSMG8 (1-
423)/CeSMG9 (59-375) 
 
Based on the result from mass spectrometry, in order to obtain a homogeneous core 
complex of CeSMG8-9, CeSMG9 (59-375) was co-expressed with CeSMG8 (1-423) in 
insect cells and purified with procedures described in Methods 4.3.7. The results of 
gel-filtration chromatography and SDS-PAGE gel shown below indicate that the C-
terminally truncated construct CeSMG9 (59-375) is sufficient to bind CeSMG8 (1-
423) and no obvious protein degradation can be observed on the gel. 
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Figure 5.11: Purification of complex CeSMG8 (1-423)/CeSMG9 (59-375). (a). Gel 
filtration chromatography on a superdex hiload-200 column. (b). 12.5% SDS-PAGE of 
selected fractions of peak of gel filtration chromatography shown in (a).  
5.11 Crystallization of complex CeSMG8 (1-423)/CeSMG9 
(59-375)  	  
Crystallization screening was set up with this core complex CeSMG8 (1-
423)/CeSMG9 (59-375), crystals shown in figure 5.12 (a) were reproduced from initial 
screening with sitting drop method at room temperature but only diffracted to 7 Å and 
had problem of anisotropy. Unexpectedly this complex can also crystallize in the same 
condition in which the complex CeSMG8 (1-423)/CeSMG9 (39-385) has crystallized. 
Crystals of complex CeSMG8 (1-423)/CeSMG9 (59-375) shown in figure 5.12 (b) 
share the same morphology with crystals of complex CeSMG8 (1-423)/CeSMG9 (39-
385) and diffracted to 3.5 Å but also had same twinning problem.  
 
Figure 5.12: Crystals of complex CeSMG8 (1-423)/CeSMG9 (59-375). (a). Crystals 
grew at room temperature in the condition of 15% PEG 10000, 0.1 M Tris-Cl, PH 8.5 
in a sitting drop containing 150 nl protein (8.7 mg/ml) and 150 nl crystallization buffer 
within 3 days. (b). Crystals grew at 10 °C in the condition of 18% PEG 4 000, 0.1 M 
Tris-Cl, PH 8.0 in a sitting drop containing 150 nl protein (8.7 mg/ml) and 150 nl 
crystallization buffer within 3 days. 
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5.12 Crystallization of complex CeSMG8 (1-423)/CeSMG9 
(59-375) with yttrium chloride and structure determination 
5.12.1 Crystallization screening and optimization 
 
In order to solve the twinning problem of hexagonal crystals of complex CeSMG8 (1-
423)/CeSMG9 (59-375), yttrium chloride was added to the protein as an additive for 
crystallization screening with the hope that protein can crystallize in a new crystal form 
without twinning problem, which is based on the previous report91 that yttrium ions 
can bind specifically to surface-exposed glutamate and aspartate side chains to create 
contact of molecules to yield high quality crystals that belong to a new space group. 
The crystals grew in the initial screening condition shown in figure 5.13 (a) were very 
small but were not hexagonal, which was a good starting point for optimization. The 
crystals can be reproduced shown in figure 5.13 (b) by changing the concentration of 
precipitant and removing ammonium sulfate in the crystallization condition. The 
crystals were further optimized with hanging drop method and grown at 10 °C. The 
optimized crystals shown in figure 5.13 (c) have very different morphology as 
compared to the twinning hexagonal crystals. The final concentration of YCl3 in 
protein sample has been constantly 0.11 mM (stock concentration is 1 mM).  
 
Figure 5.13: Crystals of complex CeSMG8 (1-423)/CeSMG9 (59-375) crystallized 
in presence of YCl3. (a). Crystals from initial screening grew at 4 °C in the condition 
of 25% PEG 3350, 0.1 M Tris-Cl, pH 8.5, 0.2 M ammonium sulfate in a sitting drop 
containing 150 nl protein (5.9 mg/ml) and 150 nl crystallization buffer. (b). Crystals 
were reproduced at 4 °C in the condition of 14% PEG 3350, 0.1 M Tris-Cl, pH 8.5 in a 
sitting drop containing 150 nl protein (5.9 mg/ml) and 150 nl crystallization buffer. (c). 
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Crystals were optimized at 10 °C and grew in the condition of 12% PEG 3350, 0.1 M 
Tris-Cl, pH 8.5 in a hanging drop containing equal volume (1 µl) protein (5.1 mg/ml) 
and crystallization buffer.  
5.12.2 Diffraction data of native crystals of complex CeSMG8 (1-
423)/CeSMG9 (59-375) 
 
The crystals were further optimized to increase the size by being grown in bigger 
hanging drop (1.5 µl protein) and changing concentration of protein and precipitant. 
The diffraction pattern and data processing result are shown below in figure 5.14. The 
crystal can diffract to around 3.6 Å and no significant twinning can be detected by 
phenix. Xtriage. The crystal belongs to space group P3221. 
 
Figure 5.14: Diffraction data of native crystals of complex CeSMG8 (1-
423)/CeSMG9 (59-375). (a). X-ray diffraction pattern. (b). Data processed by XDS. 
5.12.3 Preparation of selenium-methionine derivatized complex 
CeSMG8 (1-423)/CeSMG9 (59-375) 	  
Selenium-methionine derivatized complex CeSMG8 (1-423)/CeSMG9 (59-375) was 
expressed and purified for SAD experiment for phasing. Theoretically, 1 selenium-
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methionine residue can provide enough phasing power for 100 amino acids. 3.1% 
residues in CeSMG8 (1-423) and 2.8% residues in CeSMG9 (59-375) are methionine. 
The procedures for expression and purification of selenium-derivatized protein were 
described in Methods 4.3.8. The proteins were eluted in a homogeneous peak in gel 
filtration chromatography shown in figure 5.15 (a), however two additional bands were 
observed on the SDS-gel shown in figure 5.15 (b). These two additional bands could 
be either impurities or the degraded fragments of CeSMG8. The incorporation rate of 
selenium in CeSMG8 and CeSMG9 were analyzed by Mass Spectrometry. The results 
of molecular weight measurement shown in figure 5.15 (c) and (d) indicate the 
inhomogeneous incorporation of selenium-methionine in CeSMG8 (1-423) and 
CeSMG9 (59-375). 
 
Figure 5.15: Preparation of selenium-methionine derivatized complex CeSMG8 
(1-423)/CeSMG9 (59-375).  (a). Gel filtration chromatography on a superdex 200 
column. (b). 12.5% SDS-PAGE of fractions of peak of gel filtration chromatography 
shown in (a). (c). Molecular weight of selenium-methionine derivatized CeSMG8 (1-
423) measured by Mass Spectrometry. (d). Molecular weight of selenium-methionine 
derivatized CeSMG9 (59-375) measured by Mass Spectrometry. 
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5.12.4 Crystallization of selenium-methionine derivatized complex 
CeSMG8 (1-423)/CeSMG9 (59-375) and data collection 	  
The selenium-methionine derivatized complex CeSMG8 (1-423)/CeSMG9 (59-375) 
was crystallized in the same crystallization condition as native protein. However, like 
the native protein, the crystallization was too fast and produced over 100 very small 
crystals in one drop shown in figure 5.16 (a), which diffracted weakly and can not 
produce strong enough anomalous signals for phasing. During data collection, it was 
found that bigger crystals diffracted better than smaller ones. Therefore, efforts were 
made to increase the crystal size to get better diffracting crystals. Various methods 
were tried but only one method worked, which was adding 1 ml paraffin oil on top of 
reservoir buffer (0.7 ml) in the well based on the knowledge that paraffin oil is very 
impermeable that can slow down the vapor diffusion process and produce less and 
bigger crystals in the drop shown in figure 5.16 (b). The dataset collected from 
optimized crystal was processed with XDS shown in figure 5.16 (c) and the anomalous 
signal was strong enough for phasing.  
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Figure 5.16: Crystals of selenium-methionine derivatized complex CeSMG8 (1-
423)/CeSMG9 (59-375) and data processing. (a) Crystals grew at 10 °C with hanging 
drop method in the condition of 11% PEG 3350, 0.1 M Tris-Cl, pH 8.5 in a drop 
containing equal volume (1.5 µl) of protein (6.7 mg/ml) and crystallization buffer. (b). 
Optimized crystals grew at 10 °C with hanging drop method in the condition of 11% 
PEG 3350, 0.1 M Tris-Cl, pH 8.5 in a drop containing equal volume (1.5 µl) of protein 
(6.7 mg/ml) and crystallization buffer with 1 ml paraffin oil on top of the reservoir 
buffer in the well. (c). Processed results of dataset collected from an optimized 
selenium-methionine derivatized crystal. 
5.13 Crystal structure of C. elegans SMG8-SMG9 core 
complex  
 
The crystal structure of C. elegans SMG8-SMG9 core complex was solved at the 
resolution of 2.5 Å with procedures described in the Methods 4.9.4. Three copies of 
CeSMG8-CeSMG9 complex are present in the asymmetric unit forming a ring-like 
structure in 3 fold non-crystallographic symmetry (Figure 5.17, b). The structure model 
was refined to the final R-free of 26.3% with good stereochemistry and mostly built 
except some disordered regions. The structure shows that the previously predicted N-
terminal region of CeSMG8 actually consists of two domains, a N-terminal G-like 
domain (1-323) and a middle helical bundle domain (334-416), connected by a short 
linker of 10 residues. The C-terminal domain (59-363) of CeSMG9 is also a G-like 
domain (Figure 5.17, c). Both G-like domains are centered at a mixed β-sheet (of five 
parallel and one antiparallel β-strands) surrounded by α-helices both on the concave 
surface (α1, α5) and on the convex surface (α2, α3, α4) (Figure 5.17, d). Both 
CeSMG8 and CeSMG9 incorporate additional secondary structure elements. Two 
more helices line the convex surface of each domain (α2A, α7 in CeSMG8 and α4, α7 
in CeSMG9). The major structural difference between CeSMG8 and CeSMG9 is the 
presence in the form of a helical bundle of three C-terminal helices (α7-α9) forming a 
stalk-like protrusion, reminiscent of the stalk domain found in GTPases of the 
dynamin-like family such as Atlastin92 or GBP193.  
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Figure 5.17: The crystal structure of C. elegans SMG8-SMG9 core complex. (a). 
The domain architecture of CeSMG8 and CeSMG9 based on structural information. 
The CeSMG8 contains a N-terminal G-like domain (in orange), a middle helical 
bundle domain (in orange) and a distant domain of unknown structure and function (in 
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grey). The CeSMG9 contains a N-terminal unstructured region and a C-terminal G-like 
domain (in blue). The domain boundaries are marked with numbers. (b). Three copies 
of CeSMG8-CeSMG9 complex are in the asymmetric unit forming a ring-like 
structure. (c). Overall view of the structure model of CeSMG8-CeSMG9 core complex. 
(d). Topology diagram of CeSMG8 (1-416) and CeSMG9 (59-363). Figure was 
generated by program Pro-origami94 with structures of CeSMG8 and CeSMG9 and 
manually edited.  
5.14 CeSMG9 interacts with both domains of CeSMG8  
 
The interaction between CeSMG8 and CeSMG9 is extensive and contributed mainly 
by helices at the binding interface. The G-like domains face each other and interact 
with part of their convex surfaces. The buried surface area of CeSMG8 and CeSMG9 
calculated with program PISA95 are 1724.5 Å² (9.5 % of total solvent-accessible area) 
and 1704.5 Å² (13.7% of total solvent-accessible area), respectively. CeSMG9 G-like 
domain interacts with CeSMG8 N-terminal G-like domain as well as middle helical 
bundle domain at two major binding sites. The first binding site is on the G-like 
domain of CeSMG8 (Arg87, Lys91, Val83, Ile85), which interacts with CeSMG9 
(Glu254, Glu257, Tyr202, Leu258) with both charged interaction and hydrophobic 
interaction (shown below, left). The second binding site is composed by both CeSMG8 
G-like domain (Phe99) and helical bundle domain (Ile335, Phe338), which contacts 
CeSMG9 (Val212, Ile216, Tyr358) with hydrophobic interaction (shown below, right) 
and anchors the CeSMG8 helical bundle domain on CeSMG9. 
 
Figure 5.18: Zoom-in views of major interactions between CeSMG8 and 
CeSMG9. Left: CeSMG9 interacts with the binding site on N-terminal CeSMG8; 
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middle: overall view of the structure; right: CeSMG9 interacts with a composite 
binding site on CeSMG8 formed by the N-terminal G-like domain and the middle 
helical bundle domain.  
5.15 SMG8-SMG9 binding interface is conserved in humans 	  
In order to know whether the binding interface of CeSMG8 and CeSMG9 is conserved 
in human SMG8 and SMG9, Co-immunoprecipitation (IP) assays using mammalian 
cells were performed by Mahesh Lingaraju in the lab with human SMG8 and SMG9 
mutants designed with structure information and sequence conservation.  The Met390 
and Tyr515 in hSMG9 are conserved with Leu258 and Tyr358 in CeSMG9 
respectively based on sequence alignment (supplementary materials, S4). The results 
of Co-IP show that the single mutation M390R in hSMG9 abolished the hSMG8 
binding significantly while the single mutation Y515R did not weaken the binding. The 
double mutation M390R and Y515R abolished the hSMG8 binding almost completely. 
The results indicate that the interaction mode of SMG8-SMG9 is conserved in humans 
and the binding is stronger at the N-terminal binding site than at the C-terminal binding 
site of SMG8.  
 
Figure 5.19: Co-IP of human SMG8 and SMG9. Figure is contributed by Mahesh 
Lingaraju. 
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5.16 Crystal structure of CeSMG8-CeSMG9-GDP complex 	  
The crystal structure of CeSMG8-CeSMG9 core complex shows that both the N-
terminal domain of CeSMG8 and C-terminal domain of CeSMG9 are G-like domains 
and SMG9 was predicted to be a NTPase based on sequence analysis. To know 
whether CeSMG8 and CeSMG9 bind GTP or GDP and how they bind, native crystals 
of complex CeSMG8 (1-423)/CeSMG9 (59-375) shown in figure 5.20 (a) were soaked 
with either GTP and GTP analogues or GDP. However, datasets can only be collected 
from GDP-soaked crystals because crystals had severe cracks when soaked with GTP 
or GTP analogues even for very short time. The GDP-soaked crystals diffracted to 2.64 
Å and the structure can be solved by molecular replacement with the Apo structure of 
complex CeSMG8-CeSMG9 as search model. The GDP-soaked crystal belongs to 
same space group P3221 and contains also three copies of CeSMG8-CeSMG9 complex 
in the asymmetric unit. However, the density for a complete GDP molecule presents in 
only one copy of CeSMG9 shown in figure 5.20 (b) probably due to the crystal 
packing that blocked the access of GDP to the binding sites on other two copies of 
CeSMG9. The GDP-bound structure could be refined with final R-free of 28.27% and 
good stereochemistry. Most of the model could be built except some disordered 
regions including CeSMG8 residues 193-207, 255-288, 357-381, 422-423 and 
CeSMG9 residues 125-134, 152-172, 285-307 and 365-375. The GDP binds to the P-
loop of CeSMG9. The switch regions in CeSMG9 are not visible in the structure due to 
their conformational flexibility. No conformational change is observed in GDP-bound 
CeSMG9 structure as compared to the Apo structure. 
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Figure 5.20: The crystal structure of CeSMG8-CeSMG9-GDP complex. (a). Native 
crystals of complex CeSMG8 (1-423)/CeSMG9 (59-375) used for GDP soaking. The 
crystals were grown at 10 °C with hanging drop method in the condition of 11% PEG 
3350, 0.1 M Tris-Cl, pH 8.5 in a drop containing equal volume (1.5 µl) of protein (6.7 
mg/ml) and crystallization buffer with 1 ml paraffin oil on top of the reservoir buffer in 
the well. (b). Three copies of CeSMG8-CeSMG9 complex are in the asymmetric unit 
and GDP molecule (shown in red) is bound to only one copy of CeSMG9. (c). Domain 
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architecture of CeSMG8 and CeSMG9. (d). Overall view of the crystal structure of 
CeSMG8-CeSMG9-GDP complex shown in two orientations related by the rotation of 
90° around the vertical axis. CeSMG8 is shown in orange, CeSMG9 is shown in blue, 
GDP is shown in red. 
5.17 GDP binds to the conserved P-loop in CeSMG9  
 
Comparison with previously determined structures in protein data bank (PDB) using 
program Dali96 shows that both G-like domains of CeSMG8 and CeSMG9 resemble 
the GTPase domain of the dynamin-like family proteins hGBP1 as well as Atlastin. 
Although both CeSMG8 and CeSMG9 G-like domains share a similar overall fold with 
G-domain of hGBP1, GDP only binds to the P-loop (G1 motif) of CeSMG9 but not 
CeSMG8. Comparing the P-loops of CeSMG9 and hGBP1 G-domain, CeSMG9Lys99 
and CeSMG9Ser100 are structurally conserved with hGBP1Lys51 and hGBP1Ser52, which 
interact with phosphate groups of GMPALF4 via hydrogen bonding. Although parts of 
switch 1 and 2 are disordered in our GDP-bound structure (residues 124-134 and 152-
172, respectively), Asp150CeSMG9 in switch 2 is at the position expected for 
coordinating the magnesium ion while Thr135CeSMG9 in switch 1 is well ordered but is 
10 Å away from the position expected for coordinating the γ-phosphate. There are two 
major differences in the phosphate-binding G1-G3 motifs of CeSMG9 as compared to 
the dynamin-like family proteins (Figure 5.21, d). First, there is a conserved proline 
residue (Pro153CeSMG9) at the position of switch 2 typically occupied by a glycine. 
Second, there is a conserved glycine residue (Gly96CeSMG9) in the P loop at the 
equivalent position of the so–called arginine-finger, an important element for the in-cis 
stimulation of GTPase activity in dynamin-like proteins97,98. Another major difference 
between CeSMG9 and dynamin-like proteins is at the motifs that bind the base of the 
nucleotide. The G4 motif of CeSMG9 contains a conserved lysine residue 
(Lys241CeSMG9) instead of the aspartic acid that in hGBP1 and Atlastin mediates 
specific interactions with the guanine base. The side chain of Lys241CeSMG9 stacks on 
top of the guanine base with the aliphatic portion and points towards the phosphates of 
the nucleotide with the positively charged tip.  
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Figure 5.21: Structural comparison of CeSMG8, CeSMG9 and hGBP1 and 
sequence alignment of SMG9 and hGBP1. (a): Zoom-in view of the region in 
CeSMG8 that corresponds to the GDP-binding site in CeSMG9 based on structural 
alignment; (b): Zoom-in view of the GDP-binding site in CeSMG9. Highlighted 
residues K99 and S100 in P-loop (G1), T135 in G2, D150 in G3, T240 and K241 in G4 
are conserved as in classical G motifs in GTPases; (c): Zoom-in view of GMPALF4- 
binding site in G-domain of hGBP1. (d): Sequence alignment of SMG9 from 
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Caenorhabditis elegans, Homo sapiens, Danio rerio and human GBP1. G-motifs are 
marked with red rectangles. The secondary-structure elements of CeSMG9 are 
indicated above the sequences. 
5.18 The non-canonical G4 motif of CeSMG9 allows ATP 
binding  	  
It is likely that CeSMG9 lost its GTP binding specificity due to the non-canonical G4 
motif, therefore it is interesting to know whether CeSMG9 is able to bind ATP. I 
soaked the native crystal of complex CeSMG8 (1-423)/CeSMG9 (59-375) with ADP in 
the same way as soaking with GDP. The crystal structure of CeSMG8-CeSMG9-ADP 
was solved by molecular replacement using the structure of CeSMG8/CeSMG9 
complex as searching model. The structure was solved at 2.65 Å and contains three 
copies of CeSMG8 and CeSMG9 in the asymmetric unit. The model was refined to a 
final R-work of 24.4% and R-free of 28.3% and good stereochemistry. The density of 
ADP molecule can be observed at the same position in CeSMG9 where GDP binds. 
The phosphate groups of ADP interact with the P-loop of CeSMG9 (residues Lys99, 
Ser100) by forming a number of hydrogen bonds. Like GDP, the adenine base of ADP 
is not coordinated with specific residues. CeSMG9 lost specificity for nucleotide 
recognition due to the non-canonical G4 motif and binds both GDP and ADP with its 
conserved P-loop.  
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Figure 5.22: Crystal structure of the CeSMG8-CeSMG9-ADP complex. (a): 
Overall view of structure model. CeSMG8 is shown in orange, CeSMG9 is shown in 
blue, ADP is shown in magenta. (b): zoom-in view of ADP binding site. Highlighted 
residues are conserved in G motifs. 
5.19 CeSMG9 binds GTP and ATP with micro molar affinity 	  
The binding affinity of CeSMG9 with different nucleotides GTPγS, GDP and ATP 
were measured with Mant-labeled Fluorescence Anisotropy. The experiment procedure 
was described in Methods 4.10. CeSMG9 alone binds GDP with affinity of around 10 
µM (figure 5.23, a) and the complex CeSMG8/CeSMG9 binds GDP with affinity of 
around 15 µM (figure 5.23, b). The complex CeSMG8/CeSMG9 binds GTPγS and 
ATP with slightly higher affinity (6.5 µM and 1.5 µM, respectively) than binds GDP 
probably due to the interaction between the additional phosphate group and CeSMG9.  
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Figure 5.23: Measurement of nucleotides binding affinity of CeSMG9 and 
CeSMG8-CeSMG9 complex. (a). Measurement of GDP binding affinity of CeSMG9 
(59-375), the G-like domain of CeSMG9. (b). Measurement of GDP binding affinity of 
the complex CeSMG8 (1-423)/CeSMG9 (59-375). (c). Measurement of GTPγS 
binding affinity of the complex CeSMG8 (1-423)/CeSMG9 (59-375). (d). 
Measurement of ATP binding affinity of the complex CeSMG8 (1-423)/CeSMG9 (59-
375). 
5.20 Fitting of CeSMG8-9 into the EM density of Human 
SMG1-8-9 
  
The previously published negative-stain EM density of human SMG1-8-9 complex 
47(EMD-2663) was fitted with the crystal structure of CeSMG8-9 complex together 
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with the homology model of human SMG1 from another published EM study99 with 
UCSF Chimera100. Both the N-terminal HEAT repeats and the C-terminal kinase 
domain model of human SMG1 were fitted as two separate rigid bodies into the 
density at the contour level of 3.4 as suggested by the authors. The N-terminal HEAT 
repeats of SMG1 was fitted into the curved and tubular density (the “arm” region) by 
which the N-terminus of HEAT repeats is at the bottom and the C-terminus of HEAT 
repeats is close to the kinase domain (correlation coefficient: 0.74). The homology 
model of kinase domain was fitted into the “head” region of SMG1 (correlation 
coefficient: 0.77). After fitting of homology models of human SMG1 into the density 
map, the extra density for human SMG8-SMG9 can be fitted with our crystal structure 
of CeSMG8-9 core complex (correlation coefficient: 0.69). The fitting of CeSMG8-9 
structure in the map shows that SMG9 is at the central position in SMG1-8-9 complex, 
with the G-motif loops pointing towards the HEAT repeat region of SMG1. The fitting 
is consistent with previously reported results that SMG9 directly interacts and forms a 
stable complex with SMG148. Although the N-terminal unstructured region of 
CeSMG9 is absent in the crystal structure, the N-terminus of SMG9 might be an 
integral part of the density at the “arm” region. The fitting also indicates that the helix 
bundle domain of SMG8 points towards the C-terminal “head” region of SMG1, which 
allows the possible interaction between C-terminal “head” region of SMG1 and the C-
terminal low-complexity region of SMG8 and might lead to the inhibition of SMG1 
kinase activity. The fitting is supported by the crosslinking data reported previously 
that the residue Lys869 at the C-terminus of human SMG8 was cross-linked with the 
residue Lys2993 at the C-insertion of human SMG199. Taken together, the fitting 
provided a reasonable model of SMG1-8-9 complex supported by the visible fitting 
quality and the previous knowledge on the interaction mode among SMG1, SMG8 and 
SMG9.    
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Figure 5.24: Fitting of CeSMG8-9 into the density of human SMG1-8-9. (a). The 
overview of the fitting in two orientations associated with 90 degrees rotation around a 
vertical axis. (b). The zoom-in view of models of hSMG1, CeSMG8-9-GDP complex.  
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6 Discussion and conclusions 
 
Nonsense mediated mRNA decay (NMD) is an important mRNA quality control 
pathway conserved in eukaryotes. NMD targets aberrant mRNAs carrying premature 
stop codons (PTCs) for rapid degradation, and in doing so it prevents the accumulation 
of C-terminally truncated protein products that might otherwise be toxic to cells. NMD 
involves the concerted action of many trans-acting factors and it is a highly regulated 
process. The decisive event to trigger NMD is the phosphorylation of UPF1 by a PIKK 
kinase, SMG1. It was reported that in human cells, SMG8 and SMG9 form a 
heterodimer that interacts with SMG1 and inhibits its kinase activity. However, several 
important questions remained to be investigated, such as, how does SMG8 interact 
with SMG9 to form a heterodimer? What are the biochemical properties of SMG8 and 
SMG9? How do SMG8 and SMG9 work together to regulate SMG1 kinase activity? In 
order to address these questions, I carried out structural and biochemical analysis of 
SMG8 and SMG9. The results in this thesis work provide for the first time detailed 
structural information of the SMG8-SMG9 core complex from C. elegans and the 
structural basis for the nucleotides binding property of SMG9. 
Structural characterization of human SMG8-SMG9 complex was impeded by the fact 
that both human SMG8 and SMG9 contain many large disordered regions based on 
secondary structure prediction (supplementary materials, S2), which would cause 
problems for producing crystals for X-ray crystallography. In comparison, the C. 
elegans SMG8 and SMG9 contain less flexible regions thus were used as subjects for 
structure determination.  
The domain organization of CeSMG8 and CeSMG9 were not previously characterized, 
secondary structure predictions show that CeSMG8 contains a structured N-terminal 
region (1-423), followed by a large disordered region and a small C-terminal structured 
region. CeSMG9 contains two distinct regions, a N-terminal disordered region (1-58) 
and a C-terminal folded domain (59-385). The corresponding C-terminal domain in 
human SMG9 was predicted as a putative NTPase with analysis of sequence48.  
The expression tests of CeSMG8 and CeSMG9 were tried in E. coli first. The full-
length as well as N-terminally truncated CeSMG9 could be expressed and purified in 
isolation from E. coli. The purified CeSMG9 (39-385) and CeSMG9 (59-385) were 
subjected to crystallization screening. However, no crystal hit was obtained from these 
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two constructs. The reason could be that CeSMG9 alone is not stable in solution based 
on the observation of significant precipitation of purified CeSMG9 protein after 
overnight incubation at 4 °C. CeSMG8 (1-423) was not soluble when it was expressed 
in isolation in E. coli but could be solubilized when it was co-expressed with full-
length CeSMG9 and could be co-purified in the form of CeSMG8-CeSMG9 complex, 
indicating that the N-terminal structured region (1-423) of CeSMG8 is sufficient to 
bind CeSMG9. Although the CeSMG8-CeSMG9 complex could be purified from E. 
coli, the amount of purified protein obtained from large-scale expression was too little 
to perform crystallization experiments and in addition, protein degradation occurred 
after purification and most likely in the N-terminal intrinsically disordered region of 
CeSMG9.  
To solve these two problems, CeSMG8 (1-423) and CeSMG9 (39-385) were co-
expressed in insect cells with a baculovirus system. Milligram quantities of purified 
protein can be obtained and was used for crystallization screening. Hexagonal crystals 
were obtained within two days and were optimized to single big hexagonal crystals 
with seeding in sitting drops. Although the optimized crystals could diffract to around 
3 Å resolution, crystals suffered severe twinning defects that made structure 
determination not feasible, particularly because there was no suitable model for 
phasing by molecular replacement. A first strategy I used to try and solve the twinning 
problem was to make a shorter construct of CeSMG9 in the CeSMG8-CeSMG9 
complex with the hope of changing crystal packing. CeSMG9 (59-385), a further N-
terminally truncated CeSMG9 construct that contains only the C-terminal domain was 
co-expressed with CeSMG8 (1-423) in insect cells. After purification, two distinct 
bands appeared close to the position of CeSMG9 (59-385) on SDS-PAGE gel, which 
could be the result of degradation of CeSMG9. Results of mass spectrometry analysis 
showed that the degradation occurred at the C-terminus of CeSMG9 and identified a 
shorter fragment CeSMG9 (59-375). However, no new crystal form was obtained with 
this shorter construct and the same hexagonal crystal can be obtained but still had 
twinning problem, which suggested that the N-terminal and C-terminal truncation of 
CeSMG9 did not affect the crystal packing.  
It was reported that yttrium chloride could be used in crystallization to affect the 
crystal packing, based on previous experiences that the yttrium ion can coordinate with 
surrounding aspartic acid or glutamic acid residues of protein91. The usage of yttrium 
chloride as an additive was a successful strategy to solve the twinning problem. The 
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complex CeSMG8 (1-423)/CeSMG9 (59-375) was crystallized in presence of yttrium 
chloride and crystals with a different morphology (pyramid-like) were obtained that 
were not twinned. Selenium-methionine derivatized crystals were obtained with same 
crystallization method and in addition the crystal was optimized with paraffin oil to 
increase the crystal size and boost anomalous signal, which led to the successful 
structure determination.  
The crystal structure of CeSMG8-CeSMG9 core complex was solved at the resolution 
of 2.5 Å. The structure of CeSMG8 revealed its domain organization that the 
previously predicted N-terminal structured region (1-423) consists of two distinct 
domains, a N-terminal G-like domain (1-323) and a middle helical bundle domain 
(334-416) connected by a linker of 10 residues. The structure of CeSMG9 C-terminal 
region (59-363) also resembles a G-domain. Both G-like domains of CeSMG8 and 
CeSMG9 are structurally similar to the GTPase domain of dynamin-like family 
proteins hGBP1 and Atlastin. This led to the question that whether CeSMG8 and 
CeSMG9 are able to bind GTP. I soaked the native crystals with either GTP and its 
analogue or GDP but crystals could only survive when soaked with GDP. Therefore, 
the crystal structure of GDP-bound CeSMG8-CeSMG9 core complex was solved by 
molecular replacement. The structure revealed that GDP only binds CeSMG9 but not 
CeSMG8. Residues in the P-loop responsible for phosphate binding are indeed 
conserved in CeSMG9 but not in CeSMG8. The GDP and GTP binding affinity of 
CeSMG9 in vitro is around 10-15 µM and 6.5 µM respectively, as measured by 
fluorescence anisotropy. In general, the low-micromolar binding affinity we measured 
for CeSMG8-CeSMG9 is similar to that reported for hGBP1101. Although CeSMG9 
binds GDP with its conserved P-loop, the base recognition is not specific: because the 
non-canonical G4 motif of SMG9 lacks the conserved Aspartic acid residue that 
recognizes the guanine base by specific hydrogen bonding. The unspecific nucleotide 
binding property of CeSMG9 was confirmed by determining the crystal structure of 
ADP-bound CeSMG8-CeSMG9 complex, which was solved by using crystals soaked 
with ADP. The structure revealed that the binding mode of ADP is the same as GDP. 
The ADP molecule binds to the conserved P-loop of CeSMG9 and the adenine base is 
not coordinated by specific residues. The ATP-binding affinity of CeSMG9 is around 
1.5 µM measured by fluorescence anisotropy. Like CeSMG9, human SMG9 also 
contains a conserved P-loop and a non-canonical G4 motif therefore it is very likely 
that human SMG9 also binds nucleotides without selectivity. In addition, both 
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CeSMG9 and hSMG9 did not show GTPase activity in GTPase assays. This is possibly 
because the glycine residue that is critical for GTP hydrolysis in classical GTPases (G3 
motif DxxG) is replaced with a residue proline in SMG9 (G3 motif DxxP). In this 
context, we note that SMG9 has been reported to interact with a GTPase-activating 
protein102, which might activate SMG9 activity by providing a catalytic residue.  
The relative position of the G-like domains in the CeSMG8-CeSMG9 heterodimer is 
remarkably similar to that observed in active dimeric GTPases of the dynamin 
family97,98. In particular, CeSMG8 and CeSMG9 converge at the loops that are known 
to harbor the nucleotide-binding motifs (G motifs) in canonical GTPases. While many 
of the conserved G-motif residues are present in CeSMG9, in CeSMG8 they are 
absent. Furthermore, the single stalk domain in the CeSMG8-CeSMG9 heterodimer 
has a different relative position as compared to the conformations observed in 
dynamin-like proteins92,93. Finally, while proteins such as Atlastin or hGBP1 dimerize 
in the presence of GTP analogues92,97, the SMG8-SMG9 heterodimer is formed in the 
absence of nucleotides.  
CeSMG8 interacts with CeSMG9 extensively along the binding interface. Both G-like 
domain and helical bundle domain of CeSMG8 interact with the G-like domain of 
CeSMG9 with charged interaction and hydrophobic interaction. Co-
immunoprecipitation assays with human SMG8 and SMG9 mutants revealed that the 
interaction mode between CeSMG8 and CeSMG9 is conserved between hSMG8 and 
hSMG9. The different effects of two hSMG9 mutants in abolishing hSMG8-binding 
indicated that the binding is stronger at the N-terminal binding site than at the C-
terminal binding site of SMG8. The stronger binding at the N-terminal binding site of 
SMG8 can be explained by the structural information of CeSMG8-9 that both 
hydrophobic and charged interactions and also more residues are involved at the N-
terminal binding site of CeSMG8, while fewer residues are involved at the C-terminal 
binding site of CeSMG8. I speculate that it would be easier and more efficient for the 
conformation-flexible C-terminal helical bundle domain of SMG8 to dock on SMG9 if 
the N-terminal domain of SMG8 is already tightly bound on SMG9.  
The fitting of CeSMG8-9 structure into the EM density of human SMG1-8-9 provided 
a reasonable model for SMG1-8-9 complex. The pseudo-atomic model of SMG1-8-9 
complex revealed that SMG9 is in the central position and critical for the integrity of 
the whole complex. The G-like domain of SMG9 interacts with the N-terminal HEAT 
repeats of SMG1. Although the N-terminal unstructured region of CeSMG9 is absent 
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in the crystal structure, the N-terminus of SMG9 might be an integral part of the 
density at the “arm” region. Our fitting model also provided the structural insights into 
how SMG8 probably interacts with SMG1. The SMG1-8-9 model revealed that the N-
terminus of SMG1 is close to the G-like domain of SMG8 and their possible 
interaction is supported by the previous published crosslinking data99 which showed 
the residue Lys170 at the N-terminus of HEAT repeats of SMG1 was cross-linked with 
the residue Lys290 in the SMG8 G-like domain. The conformation of CeSMG8 helical 
bundle domain is fixed by docking on the CeSMG9, which would orient the SMG8 C-
terminal region to the C-terminal “head” region of SMG1 as revealed in the fitting 
model of SMG1-8-9 and is consistent with the previous published crosslinking data99 
which showed that the residue Lys869 at the C-terminus of human SMG8 was cross-
linked with the residue Lys2993 at the C- insertion region of human SMG1. Therefore, 
SMG8 is likely to interact with both the N-terminus and C-terminus of SMG1 with its 
N-terminal G-like domain and C-terminus, respectively. The model also has predictive 
value, as it raises the hypothesis that the switch regions of the SMG9 G-like domain 
might become ordered upon SMG1 binding and therefore that the nucleotide-binding 
state of SMG9 might impact on the conformation of the entire complex.  
To conclude, in this thesis, I have solved the crystal structures of C. elegans SMG8-9 
core complex in its Apo, GDP and ADP-bound forms at the resolution of 2.49, 2.64, 
2.65 Å respectively. The structures characterized interactions between CeSMG8 and 
CeSMG9, CeSMG9 and nucleotides. The conservation of SMG8-9 interaction was 
confirmed by the Co-IP experiment with human SMG8-9. In addition, the fitting model 
of SMG1-8-9 provided structural insights into how SMG8 and SMG9 interact with 
SMG1 to assemble a stable complex. This fitting model together with previously 
published biochemical data have helped us significantly to understand the molecular 
mechanism underlying the regulation of kinase SMG1 by its two regulators, SMG8 and 
SMG9. This model paves the way to future studies to understand whether and how the 
nucleotide-binding properties of SMG8-SMG9 affect the function of the SMG1 kinase. 
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Supplementary materials  
 
S1. Table 1 
 
Data	  Collection	  and	  Refinement	  Statistics	  
Dataset CeSMG8-9-Apo CeSMG8-9-GDP CeSMG8-9-ADP 
Wavelength (Å) 0.979  0.9785  1.2547 
Resolution range 
(Å)
a
 
52.36  - 2.493 
(2.583  - 2.493) 
47.48  - 2.64 
(2.734  - 2.64) 
62.71  - 2.649 
(2.744  - 2.649) 
Space group P 32 2 1 P 32 2 1 P 32 2 1 
a, b, c (Å) 
111.085 111.085 
374.474  
110.605 110.605 
360.266  
111.129 111.129 
376.232  
α, β, γ (°) 90 90 120 90 90 120 90 90 120 
Total reflections
a
 3768766 (360260) 764628 (71339) 752149 (22133) 
Unique reflections
a
 94467 (9210) 76172 (7433) 76844 (6129) 
Multiplicity
a
 39.9 (39.1) 10.0 (9.6) 9.8 (3.6) 
Completeness (%)
a
 1.00 (0.98) 1.00 (0.99) 0.97 (0.78) 
Mean I/sigma(I)
a
 27.25 (1.61) 12.39 (1.85) 16.40 (0.76) 
R-merge
a
 0.1374 (2.587) 0.1198 (1.09) 0.1019 (1.358) 
CC1/2
a
 1 (0.783) 0.998 (0.793) 0.999 (0.349) 
Refinement 
R-work 0.2161  0.2329  0.2442  
R-free 0.2631  0.2827  0.2830  
Average B-factor 86.56 76.57 88.62 
Ligands   GDP, Mg, EDO ADP 
Water 48 78 39 
Stereochemistry 
RMS (bonds) 0.007 0.005 0.010 
RMS (angles) 1.01 0.84 1.06 
Ramachandran 
favored (%) 95 95 96 
Ramachandran 
allowed (%) 3.9 4.5 3.6 
Ramachandran 
outliers (%) 0.9 0.75 0.39 
a
Values in parentheses correspond to the highest-resolution shell. 
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S2. Prediction of disordered regions in SMG8 and SMG9 
 
Sequences of SMG8 and SMG9 from both C. elegans and humans were submitted to 
DISOPRED3103 to predict the intrinsic disordered regions. Amino acids in the input 
sequence are considered disordered when the blue line is above the grey dashed line, 
that is the confidence score higher than 0.5. The orange line shows the confidence of 
disordered protein binding residue predictions. The results shown below indicate that 
SMG8 and SMG9 from C. elegans contain less disordered regions than their human 
orthologues. The results also show that both CeSMG8 and hSMG8 contain a large 
disordered region in the middle of their sequences, which separates the N-terminal and 
C-terminal structured regions. The predictions also show that both CeSMG9 and 
hSMG9 contain a N-terminal large disordered region followed by a C-terminal 
structured region. The results suggest that SMG8 as well as SMG9 might have similar 
domain organizations in C. elegans and humans. 
Figure S1: Prediction of disordered regions in SMG8 and SMG9 from C. elegans 
and humans. 
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S3. Sequence alignments of SMG8  
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Figure S2: Sequence alignment of SMG8. Ce: Caenorhabditis elegans; Hs: Homo 
sapiens; Dr: Danio rerio; Dm: Drosophila melanogaster. 
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S4. Sequence alignments of SMG9 
 
 
Figure S3: Sequence alignment of SMG9. Ce: Caenorhabditis elegans; Hs: Homo 
sapiens; Dr: Danio rerio; Dm: Drosophila melanogaster. 
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